<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        176-276-20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2013
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CELSENTRI 150MG F.C. TABLETS
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        MARAVIROC
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        150
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        60
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        3106.2
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="PFIZER" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            PFIZER
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 354]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            SAUDI INTERNATIONAL TRADING COMPANY LTD (SITCO)
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Glaxo Saudi Arabia Ltd.
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        J05AX09
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>CELSENTRI contains a medicine called maraviroc. Maraviroc belongs to a group of medicines called <em>CCR5 antagonists</em>. CELSENTRI works by blocking a receptor called CCR5 which HIV uses to enter and infect your blood cells.</p><p><strong>CELSENTRI is used to treat Human Immunodeficiency Virus type-1 (HIV-1) in adults</strong></p><p>CELSENTRI must be taken in combination with other medicines which are also used to treat the HIV infection. These medicines are all called anti-HIV medicines or antiretrovirals.</p><p>CELSENTRI, as part of combination therapy, reduces the amount of virus in your body, and keeps it at a low level. This helps your body to increase the CD4 cell count in your blood. CD4 cells are a type of white blood cell that are important in helping your body to fight infection.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not take CELSENTRI:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to maraviroc or to peanut or soya or to any of the other ingredients of CELSENTRI (listed in section 6 ).</p><p>&egrave; <strong>Check with your doctor</strong> if you think this applies to you.</p><p><strong>Warnings and precautions</strong><!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
mso-ansi-language:EN-GB;mso-no-proof:yes'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_bcbe3a96-e8d9-4702-b1fe-df4fbf026e33 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
mso-ansi-language:EN-GB;mso-no-proof:yes'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Talk to your doctor or pharmacist before taking CELSENTRI.</p><p>Your doctor must take blood samples to test whether CELSENTRI is an appropriate treatment for you.</p><p>Some people taking CELSENTRI have developed serious allergic reactions or skin reactions (<em>see also &lsquo;Serious side effects&rsquo; in section 4</em>).</p><p>Before taking this medicine, make sure that your doctor knows if you have or in the past had any of the following:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>liver </strong>problems, including chronic <strong>hepatitis </strong>B or C. Only a limited number of people with liver problems have taken CELSENTRI. Your liver function may need to be closely monitored. &nbsp;<em>(See also &lsquo;Liver problems&rsquo; in section 4).</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>low blood pressure</strong>, including dizziness when you stand up or sit up quickly, or if you are taking any medicines to lower blood pressure. This is due to a sudden fall in blood pressure. If this happens, lie down until you feel better. When getting up, do so as slowly as possible.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Tuberculosis (TB)</strong> or serious <strong>fungal infections</strong>. CELSENTRI could potentially increase your risk of developing infections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>kidney problems. </strong>This is <strong>particularly important</strong> if you are also taking some other medicines (see &lsquo;Other medicines and CELSENTRI&rsquo; later in section 2).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>problems with your heart or circulatory system. </strong>Only a limited number of people with serious heart or circulatory problems have taken CELSENTRI.</p><p>&egrave;&nbsp; <strong>Tell your doctor</strong> before starting treatment if you think any of these apply to you.</p><p>&nbsp;</p><p><strong>Conditions you need to look out for</strong><!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
mso-ansi-language:EN-GB;mso-no-proof:yes'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_88e01f81-8bcc-4530-9905-9d1bf7e78bfc \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
mso-ansi-language:EN-GB;mso-no-proof:yes'><span style='mso-element:field-end'></span></span><![endif]--></p><p>Some people taking medicines for HIV infection develop other conditions, which can be serious. These include:</p><p>&nbsp; symptoms of infections and inflammation</p><p>&nbsp; joint pain, stiffness and bone problems</p><p>You need to know about important signs and symptoms to look out for while you&rsquo;re taking CELSENTRI.</p><p><strong>&egrave;&nbsp; Read the information &lsquo;Other possible side effects of combination therapy for HIV&rsquo; in Section 4 of this leaflet.</strong></p><p><strong>Older people</strong><!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
mso-ansi-language:EN-GB;mso-no-proof:yes'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_a74f726a-874c-417c-ae93-2c82731d06be \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
mso-ansi-language:EN-GB;mso-no-proof:yes'><span style='mso-element:field-end'></span></span><![endif]--></p><p>CELSENTRI has only been taken by limited numbers of people 65 years or older. If you belong to this age group, discuss with your doctor if you can use CELSENTRI.</p><p>&nbsp;</p><p><strong>Other medicines and CELSENTRI</strong><!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
mso-ansi-language:EN-GB;mso-no-proof:yes'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_28fc6062-aa1b-4a3a-94d7-ee49e6608c58 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
mso-ansi-language:EN-GB;mso-no-proof:yes'><span style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Tell your doctor or pharmacist if you are taking any other medicines</strong>, have recently taken, or might take any other medicines.<!--[if supportFields]><b style='mso-bidi-font-weight:normal'><span
lang=EN-US style='font-size:11.0pt;font-family:"Times New Roman Bold",serif;
mso-ansi-language:EN-US;mso-fareast-language:EN-US'><span style='mso-element:
field-begin'></span></span></b><span style='font-size:11.0pt'> DOCVARIABLE
vault_nd_4f5dd70c-bad6-460a-8765-88929bf45f41 \* MERGEFORMAT </span><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:11.0pt;
font-family:"Times New Roman Bold",serif;mso-ansi-language:EN-US;mso-fareast-language:
EN-US'><span style='mso-element:field-separator'></span></span></b><![endif]-->&nbsp;<!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span lang=EN-US style='font-size:11.0pt;
font-family:"Times New Roman Bold",serif;mso-ansi-language:EN-US;mso-fareast-language:
EN-US'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>Tell your doctor or pharmacist if you begin taking a new medicine while taking CELSENTRI.</p><p>Medicines containing <strong>St. John&rsquo;s Wort</strong> (<em>Hypericum perforatum</em>) are likely to prevent CELSENTRI from working properly.<strong> You should not take them</strong> <strong>while you&rsquo;re taking CELSENTRI.</strong></p><p>Some medicines may change the amount of CELSENTRI in the body when they are taken at the same time as CELSENTRI. These include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines to treat <strong>HIV</strong> or <strong>hepatitis C</strong> infection (such as atazanavir, cobicistat, darunavir, efavirenz, etravirine, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, boceprevir, telaprevir).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>antibiotics</strong> (clarithromycin, telithromycin, rifampicin, rifabutin).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>antifungal </strong>medicines (ketoconazole, itraconazole, fluconazole).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>anticonvulsant </strong>medicines (carbamazepine, phenytoin, phenobarbital).</p><p>&egrave; <strong>Tell your doctor</strong> if you are taking any of these medicines. This will allow your doctor to prescribe the right dose of CELSENTRI.</p><p>&nbsp;</p><p><strong>Pregnancy<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
mso-ansi-language:EN-GB;mso-no-proof:yes'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_e002901d-363f-4755-b2ac-5816a728ec76 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
mso-ansi-language:EN-GB;mso-no-proof:yes'><span style='mso-element:field-end'></span></span><![endif]-->&amp; Breast-feeding</strong></p><p>If you are pregnant, if you become pregnant, or if you are planning to have a baby:</p><p>&egrave; <strong>Talk to your doctor</strong> about the risks and benefits of taking CELSENTRI.</p><p>Breast-feeding<strong> is not recommended </strong>in women living with HIV, because HIV infection can be passed on to the baby in breast milk.&nbsp;</p><p>It is not known whether the ingredients in CELSENTRI can also pass into breast milk. If you are breast-feeding, or thinking about breast-feeding, you should <strong>discuss it with your doctor as soon as possible.</strong></p><p><strong>&nbsp;</strong></p><p><strong>Driving and using machines</strong><!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
mso-ansi-language:EN-GB;mso-no-proof:yes'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_38f46f50-a003-49b6-aea3-20be946c53e2 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
mso-ansi-language:EN-GB;mso-no-proof:yes'><span style='mso-element:field-end'></span></span><![endif]--></p><p>CELSENTRI can make you dizzy.</p><p>&egrave; <strong>Do not drive, cycle, or operate tools or machines</strong> unless you are sure you&rsquo;re not affected.</p><p><strong>CELSENTRI contains soya lecithin and sodium.</strong><!--[if supportFields]><span style='mso-bidi-font-size:11.0pt;
font-family:"Times New Roman",serif;mso-ansi-language:EN-GB;mso-no-proof:yes'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_70f58c4f-ed15-43eb-9e5a-f3bc2c56c94c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
mso-ansi-language:EN-GB;mso-no-proof:yes'><span style='mso-element:field-end'></span></span><![endif]--></p><p>If you are allergic to peanut or soya do not use this medicinal product.</p><p>CELSENTRI contains less than 1&nbsp;mmol sodium (23&nbsp;mg) in each&nbsp;tablet, that is to say essentially &lsquo;sodium free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take or give this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p>Your doctor will advise you whether it is better to take CELSENTRI oral solution, if you are unable to swallow tablets.</p><p><strong>How much to take</strong></p><p><strong>Adults</strong></p><p><strong>The recommended dose of CELSENTRI<sup> </sup>is 150&nbsp;mg, 300&nbsp;mg or 600&nbsp;mg twice per day </strong>depending on other<strong> </strong>medicines that you are taking at the same time. Always take the dose recommended by your doctor.</p><p><strong>&nbsp;People with kidney problems </strong></p><p>If you have a kidney problem, your doctor may alter your dose.</p><p>&egrave; <strong>Talk to your doctor </strong>if this applies to you.</p><p>&nbsp;</p><p><strong>CELSENTRI can be taken with or without food.</strong> CELSENTRI should always be taken by mouth.</p><p>CELSENTRI must be taken in combination with other medicines to treat HIV. Refer to the Package Leaflets of these other medicines for guidance on how to take them.</p><p>If you take or give more CELSENTRI than you should<!--[if supportFields]><span style='mso-bidi-font-size:
11.0pt;font-family:"Times New Roman",serif;mso-ansi-language:EN-GB;mso-no-proof:
yes'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_64447c61-91e7-45a7-ab19-5f4da5c470ca \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-size:11.0pt;font-family:"Times New Roman",serif;
mso-ansi-language:EN-GB;mso-no-proof:yes'><span style='mso-element:field-end'></span></span><![endif]--></p><p>If you accidentally take or give too much CELSENTRI:</p><p>&egrave; <strong>Contact your doctor or the nearest hospital immediately</strong>.</p><p>&nbsp;</p><p><strong>If you forget to take or give CELSENTRI</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt'><span
style='mso-element:field-begin'></span> DOCVARIABLE vault_nd_fb7d7873-fdb5-4a0e-9498-cb6e1ec58001
\* MERGEFORMAT <span style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>If you miss a dose of CELSENTRI, take or give the missed dose as soon as possible and then continue with the next dose at its regular time.</p><p>If it is almost time for the next dose, do not take or give the missed dose. Wait for the next dose at its regular time.</p><p><strong>Do not take or give a double dose to make up for a forgotten dose.</strong></p><p><strong>If you stop taking CELSENTRI</strong><!--[if supportFields]><b style='mso-bidi-font-weight:
normal'><span style='font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_71820c46-3363-4cb0-95ec-b9e4698abe41 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt'><span
style='mso-element:field-end'></span></span></b><![endif]--></p><p>Keep taking CELSENTRI until your doctor tells you to stop.</p><p>Taking your medicines at the right time every day is important as it makes sure the HIV infection does not increase in your body.&nbsp; Therefore, unless your doctor tells you to stop treatment, it is important to keep taking CELSENTRI correctly, as described above.&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or your pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. Tell your doctor if you notice anything unusual about your own health.</p><p><strong>Serious side effects &mdash; get medical help immediately</strong><!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_e9f90969-c577-4ab2-97a0-100220fa806a \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:12.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p><strong>Serious allergic or skin reactions</strong><!--[if supportFields]><span style='font-size:
11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:major-bidi;
mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_8c10b6fe-1882-4c20-a5f8-313135ac689c \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>Some people taking CELSENTRI have developed severe and life-threatening skin reactions and allergic reactions. These are rare, and may affect up to 1 in 1,000 people taking CELSENTRI.</p><p>If you get any of the following symptoms while you&rsquo;re taking CELSENTRI :</p><p>&nbsp; swelling of the face, lips or tongue</p><p>&nbsp; difficulty breathing</p><p>&nbsp; widespread skin rash</p><p>&nbsp; fever (high temperature)</p><p>&nbsp; blisters and peeling skin, particularly around the mouth, nose, eyes and genitals.</p><p>&egrave; <strong>Get medical help immediately</strong> if you get these symptoms. <strong>Stop taking CELSENTRI</strong>.</p><p>&nbsp;</p><p><strong>Liver Problems<!--[if supportFields]><span style='font-size:11.0pt;font-family:
"Times New Roman",serif;mso-ascii-theme-font:major-bidi;mso-hansi-theme-font:
major-bidi;mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_6b7e34c7-c10f-47d5-8fda-1ab9f3766dea \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;</strong><!--[if supportFields]><span
style='font-size:11.0pt;font-family:"Times New Roman",serif;mso-ascii-theme-font:
major-bidi;mso-hansi-theme-font:major-bidi;mso-bidi-theme-font:major-bidi'><span
style='mso-element:field-end'></span></span><![endif]--></p><p>These are rare, and may affect up to 1 in 1,000 people taking CELSENTRI.</p><p>Signs include:</p><ul><li>loss of appetite</li><li>feeling sick or being sick</li><li>yellowing of skin or eyes</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; skin rash or itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling very tired</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stomach pain or tenderness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; dark urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drowsiness and confusion</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fever (high temperature).</p><p>&egrave; <strong>Contact a doctor immediately</strong> if you get these symptoms. <strong>Stop taking CELSENTRI.</strong></p><p><strong>Other side effects</strong></p><p><strong>Common side effects</strong></p><p>These may affect<strong> 1 to 10 in 100 people</strong>:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diarrhoea, feeling sick, stomach ache, wind (flatulence),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; loss of appetite</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; headache, problems sleeping, depression</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; rash <em>(see also &lsquo;Serious allergic or skin reactions&rsquo; earlier in section 4)</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling weak or lack of energy, anaemia (seen in blood test result)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; increase in liver enzymes (seen in blood test results), which can be a sign of liver problems (<em>see also &lsquo;Liver problems&rsquo; earlier in section 4</em>).</p><p><strong>Uncommon side effects</strong></p><p>These may affect up to <strong>1 in 100 people</strong>:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lung infection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fungal infection of the gullet (<em>oesophagus</em>)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; fits <em>(seizures).</em></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; feeling dizzy, faint or light headed when standing up</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; kidney failure, protein in the urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an increase in&nbsp;a substance known as CPK (seen in blood test results) which is a sign that muscles are inflamed or damaged.</p><p><strong>Rare side effects </strong></p><p>These may affect up to <strong>1 in 1,000 people:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; chest pain (caused by reduced blood flow to the heart).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in muscle size</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; some types of cancer, such as of the gullet (oesophagus) and bile duct</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; decrease in number of blood cells (seen in blood test results).</p><p>&nbsp;</p><p><strong>Other possible side effects of combination therapy for HIV</strong></p><p>People taking combination therapy for HIV may get other side effects.</p><p><strong>Symptoms of infection and inflammation</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_10f82e20-557a-447b-966c-8b68309ec1e5 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>People with advanced HIV infection (AIDS) have weak immune systems, and are more likely to develop serious infections (opportunistic infections). When they start treatment, the immune system becomes stronger, so the body starts to fight infections.</p><p><strong>Symptoms of infection and inflammation may develop, caused by either:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; old, hidden infections flaring up again as the body fights them</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; the immune system attacking healthy body tissue (autoimmune disorders).</p><p><strong>The symptoms of autoimmune disorders</strong> may develop many months after you start taking medicine to treat your HIV infection. Symptoms may include:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; muscle weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; weakness beginning in the hands and feet and moving up towards the trunk of the body</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; palpitations or tremor</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hyperactivity (excessive restlessness and movement).</p><p>If you get any symptoms of infection or if you notice any of the symptoms above:</p><p><strong>&egrave;</strong><strong> Tell your doctor immediately</strong>. Don&rsquo;t take other medicines for the infection without your doctor&rsquo;s advice.</p><p>&nbsp;</p><p><strong>Joint pain, stiffness and bone problems</strong></p><p>Some people taking combination therapy for HIV develop a condition called <em>osteonecrosis</em>. With this condition, parts of the bone tissue die because of reduced blood supply to the bone.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; It is not known how common this condition is. You may be more likely to develop it if you have been taking combination therapy for a long time</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are also taking anti-inflammatory medicines called corticosteroids</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you drink alcohol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a very weak immune system</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are overweight</p><p>&nbsp;</p><p><strong>Signs to look out for include:</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_4d4cf8ee-392c-4310-87ee-43904b4acfc7 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></b><![endif]--><strong>&nbsp;</strong><!--[if supportFields]><b
style='mso-bidi-font-weight:normal'><span style='font-size:11.0pt;mso-ascii-font-family:
"Times New Roman";mso-ascii-theme-font:major-bidi;mso-hansi-font-family:"Times New Roman";
mso-hansi-theme-font:major-bidi;mso-bidi-font-family:"Times New Roman";
mso-bidi-theme-font:major-bidi'><span style='mso-element:field-end'></span></span></b><![endif]--></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; stiffness in the joints</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; aches and pains (especially in the hip, knee or shoulder)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; difficulty moving</p><p>&nbsp;</p><p>If you notice any of these symptoms:</p><p><strong>&egrave;</strong><strong> Tell your doctor</strong>.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the sight and reach of children.</p><p>Do not use CELSENTRI after the expiry date which is stated on the carton, blister or bottle label. The expiry date refers to the last day of that month.</p><p>Do not store CELSENTRI above 30&deg;C</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active ingredient in CELSENTRI is maraviroc. Each film-coated tablet contains either 150&nbsp;mg or 300&nbsp;mg of maraviroc.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p><u>Tablet core:</u> cellulose microcrystalline, calcium hydrogen phosphate anhydrous, sodium starch glycolate, magnesium stearate</p><p><u>Film-coat:</u> poly (vinyl alcohol), titanium dioxide, macrogol 3350, talc, soya lecithin, indigo carmine aluminium lake (E132).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                CELSENTRI film-coated tablets are blue coloured with “MVC 150” or “MVC 300”.
CELSENTRI 150 mg and 300 mg film-coated tablets are supplied in bottles of 180 tablets or in blister packs of 30, 60, 90 film-coated tablets and multipacks containing 180 (2 packs of 90) film-coated tablets.
Not all pack sizes may be marketed in all countries.

Celsentri is a trademark owned by or licenced to ViiV Healthcare group of companies.
© 2023 ViiV Healthcare group of companies. All rights reserved.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Manufacturing: </strong></p><p>Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg, Mooswaldallee 1,79090 Freiburg, Germany</p><p>&nbsp;</p><p><strong>Marketing Authorisation Holder:</strong></p><p>Glaxo Saudi Arabia Ltd.*, Jeddah, Kingdom of Saudi Arabia</p><p>*member of GSK group of companies</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Version Number: EMAv13
Version Date: 19 August 2022
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">يشتمل سيلسينتري على دواء يُسمَّى مارافايروك. ينتمي مارافايروك إلى فئة من الأدوية يُطلَق عليها اسم <em>مضادات</em> <em>CCR5</em>.<br />يعمل سيلسينتري على إحصار مستقبل يُسمَّى CCR5 والذي يستخدمه فيروس نقص المناعة البشرية (HIV) للدخول إلى خلايا الدم لديك وإصابتها.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يُستخدَم سيلسينتري لعلاج النمط الأول من فيروس نقص المناعة البشرية </strong><strong>(HIV-1)</strong><strong> لدى البالغين</strong></p><p dir="RTL">يجب استخدام سيلسينتري مع الأدوية الأخرى التي تُستخدَم أيضًا لعلاج العدوى بفيروس نقص المناعة البشرية. يُطلق على هذه الأدوية جميعًا اسم الأدوية المضادة لفيروس نقص المناعة البشرية أو مضادات الفيروسات الرجعية.</p><p dir="RTL">يعمل سيلسينتري، كجزء من علاج مركب، على التقليل من انتشار الفيروس في جسمك، ويبقيه عند مستوى منخفض. ويساعد ذلك جسمك على زيادة عدد خلايا CD4 في الدم. وتُعد خلايا CD4 نوعًا من خلايا الدم البيضاء التي لها دور مهم في مساعدة الجسم على مكافحة العدوى.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>لا تتناول سيلسينتري:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية لمارافايروك أو الفول السوداني أو فول الصويا أو أي من المكوِّنات الأخرى لسيلسينتري (المدرجة في القسم 6).</p><p dir="RTL">&ccedil;&nbsp;&nbsp;&nbsp; <strong>استشر طبيبك</strong> إذا كنت تعتقد أن هذه الحالة تنطبق عليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تحذيرات واحتياطات</strong><!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='mso-bidi-font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif;mso-bidi-font-weight:bold'><span dir=RTL></span><span
dir=RTL></span> </span><span dir=LTR style='mso-bidi-font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;mso-bidi-font-weight:bold'>VAULT_ND_2aba6535-d4e6-4284-bb0c-a413db0d13a6
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">استشر طبيبك أو الصيدلى قبل تناول سيلسينتري.</p><p dir="RTL">يجب أن يقوم طبيبك بأخذ عينات دم لتحليلها ومعرفة ما إذا كان سيلسينتري علاجًا مناسبًا لك أم لا.</p><p dir="RTL">أصيب بعض الأشخاص الذين يتناولون سيلسينتري بتفاعلات جلدية أو تفاعلات تحسسية شديدة <em>(راجع أيضًا &quot;الآثار الجانبية الخطيرة&quot; في القسم </em><em>4</em><em>).</em></p><p dir="RTL">قبل تناول هذا الدواء، تَأكَّد من أن طبيبك يعرف ما إذا كنت تعاني في الوقت الحالي، أو عانيت في الماضي، من أي من<br />المشاكل التالية:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في <strong>الكبد</strong>، بما في ذلك <strong>التهاب الكبد المزمن </strong>B أو C. لم يتناول سيلسينتري من المرضى الذين يعانون من مشاكل في الكبد إلا عدد محدود. قد تحتاج إلى مراقبة وظائف الكبد لديك بعناية. <em>&nbsp;(راجع أيضًا &quot;مشاكل الكبد&quot; في القسم </em><em>4</em><em>)</em>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>انخفاض ضغط الدم</strong>، بما في ذلك الشعور بدوار عند الوقوف أو الجلوس من الرقود بسرعة، أو إذا كنت تتناول أي أدوية لخفض ضغط الدم. ويحدث ذلك نتيجة الانخفاض المفاجئ في ضغط الدم. إذا حدث ذلك، ينبغي لك الاستلقاء لبعض الوقت إلى أن تشعر بتحسّن. وعند النهوض بعد الاستلقاء، ينبغي أن يكون ذلك بأكبر قدر ممكن من البطء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>السل </strong><strong>(TB)</strong> أو حالات <strong>العدوى الفطرية</strong> الخطيرة :من المحتمل أن يتسبب سيلسينتري في زيادة مخاطر الإصابة بحالات عدوى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل الكلى.</strong> ويُعدّ هذا في <strong>غاية الأهمية </strong>إذا كنت تتناول أيضًا بعض الأدوية الأخرى (راجع &quot;الأدوية الأخرى وسيلسينتري&quot; لاحقًا في القسم 2).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>مشاكل في القلب أو الجهاز الدوري. </strong>لم يتناول سيلسينتري من المرضى الذين يعانون من مشاكل خطيرة في القلب أو الجهاز الدوري إلا عدد محدود.</p><p dir="RTL">&ccedil;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أخبر طبيبك</strong> قبل بدء العلاج إذا كنت تعتقد أن أيًا من هذه الحالات تنطبق عليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>حالات ينبغي الانتباه لها</strong></p><p dir="RTL">يصاب بعض الأشخاص الذين يتناولون أدوية لعلاج &rlm;‫عدوى فيروس نقص المناعة البشرية بحالات أخرى يمكن أن تكون خطيرة. ويشمل ذلك ما يلي:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أعراض العدوى والالتهاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبس وألم في المفاصل ومشاكل في العظام</p><p dir="RTL">&nbsp;</p><p dir="RTL">عليك معرفة معلومات عن العلامات والأعراض المهمة التي ينبغي الانتباه لها أثناء تناول سيلسينتري.</p><p dir="RTL">&ccedil; اقرأ المعلومات الموجودة في &quot;الآثار الجانبية الأخرى المحتملة للعلاج المركب لفيروس نقص المناعة البشرية&quot; &nbsp;في القسم 4 من هذه النشرة.</p><p dir="RTL"><strong>كبار السن</strong></p><p dir="RTL">لم يتناول سيلسينتري من الأشخاص الذين يبلغون من العمر 65 عامًا أو أكثر إلا أعداد محدودة. إذا كنت تنتمي إلى هذه الفئة العمرية، فناقش طبيبك لمعرفة ما إذا كان يمكنك استخدام سيلسينتري أم لا.</p><p dir="RTL"><strong>الأدوية الأخرى وسيلسينتري<!--[if supportFields]><span lang=AR-SA
style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='mso-bidi-font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif;mso-bidi-font-weight:bold'><span dir=RTL></span><span
dir=RTL></span> </span><span dir=LTR style='mso-bidi-font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;mso-bidi-font-weight:bold'>VAULT_ND_9382ce9c-8f42-4c98-a127-177f1fff86f0
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;</strong><!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">أخبر الطبيب أو الصيدلي إذا كنت تتناول حاليًا أي أدوية أخرى أو تناولت مؤخرًا أو قد تتناول أي أدوية أخرى.<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
font-weight:normal'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
font-weight:normal'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
font-weight:normal'><span dir=RTL></span><span dir=RTL></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
font-weight:normal'>VAULT_ND_3a687798-ff7a-472f-a957-e091d3240049 \*
MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
font-weight:normal'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
font-weight:normal'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">أبلغ الطبيب أو الصيدلي إذا بدأت تناول دواء جديد أثناء تناولك لسيلسينتري.</p><p dir="RTL">من المرجح أن تؤدي الأدوية التي تحتوي على <strong>نبتة سانت جونز</strong> <em>(العرن المثقوب)</em> إلى منع سيلسينتري من العمل بشكل صحيح. <strong>ويجب ألا تأخذ هذه الأدوية أثناء تناول سيلسينتري&rlm;</strong><strong>&lrm;</strong><strong>.</strong></p><p dir="RTL">قد تعمل بعض الأدوية على تغيير كمية سيلسينتري في الجسم عند تناولها في الوقت نفسه الذي تتناول فيه سيلسينتري.<br />ويشمل ذلك ما يلي:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى المُستخدَمة لعلاج <strong>عدوى فيروس نقص المناعة البشرية</strong> أو <strong>التهاب الكبد الوبائي </strong><strong>C</strong><br />(على سبيل المثال &rlm;‫أتازاناڤير وكوبيسيستات وداروناڤير وإيفافيرينز&rlm;‫ وإتراڤيرين وفوسامبريناڤير وإنديناڤير ولوبيناڤير ونيلفيناڤير وريتوناڤير&rlm;‫ وساكويناڤير وبوسيبريڤير وتيلابريڤير).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>المضادات الحيوية</strong> (&rlm;‫كلاريثروميسين وتليثروميسين و&rlm;ريفامبيسين وريفابوتين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية <strong>المضادة للفطريات</strong> (كيتوكونازول وإيتراكونازول وفلوكونازول).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية <strong>المضادة للاختلاج</strong> (كاربامازيبين وفينيتوين وفينوباربيتال).</p><p dir="RTL">&nbsp;</p><p dir="RTL">&ccedil;&nbsp;&nbsp;&nbsp; <strong>يجب إبلاغ الطبيب</strong> في حالة تناولك لأيّ من هذه الأدوية. فسيتيح ذلك للطبيب تحديد جرعة سيلسينتري المناسبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الحمل<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='mso-bidi-font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif;mso-bidi-font-weight:bold'><span dir=RTL></span><span
dir=RTL></span> </span><span dir=LTR style='mso-bidi-font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;mso-bidi-font-weight:bold'>VAULT_ND_5dec90db-f704-49ff-9c4d-5ca25f11f425
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]-->والرضاعة الطبيعية</strong></p><p dir="RTL">إذا &rlm;‫كنتِ حاملاً أو إذا أصبحتِ حاملاً أو إذا كنتِ تخططين للإنجاب:</p><p dir="RTL">&ccedil;&nbsp;&nbsp;&nbsp; <strong>ف</strong><strong>تحدثي مع طبيبك</strong> حول مخاطر وفوائد تناول سيلسينتري.</p><p dir="RTL"><strong>لا ينصح</strong> بالرضاعة الطبيعية للنساء المتعايشات مع فيروس نقص المناعة البشرية،<strong> </strong>لأن عدوى فيروس نقص المناعة البشرية يمكنها الانتقال إلى الطفل عبر لبن الأم.</p><p dir="RTL">لا تتوفر أيضًا معلومات حول إمكانية انتقال مكوّنات سيلسينتري إلى لبن الأم. إذا كنتِ ترضعين طفلكِ رضاعة طبيعية أو تفكرين<br />في ذلك،<strong> يجب استشارة طبيبكِ فى أسرع وقت</strong>.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>القيادة واستخدام الآلات</strong><!--[if supportFields]><span lang=AR-SA style='mso-bidi-font-size:
11.0pt;line-height:115%;font-family:"Arial",sans-serif;mso-bidi-font-weight:
bold'><span style='mso-element:field-begin'></span> </span><span dir=LTR
style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='mso-bidi-font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif;mso-bidi-font-weight:bold'><span dir=RTL></span><span
dir=RTL></span> </span><span dir=LTR style='mso-bidi-font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;mso-bidi-font-weight:bold'>VAULT_ND_e2398941-e2e4-4590-a50d-790b1121866f
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">يمكن أن يسبب سيلسينتري الدوار.</p><p dir="RTL">&ccedil;&nbsp;&nbsp;&nbsp; <strong>تَجنّب القيادة أو ركوب الدراجة أو تشغيل الأدوات أو الآلات</strong> ما لم تتأكد من عدم تأثرك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يحتوي سيلسينتري على ليسيثين الصويا و الصوديم.</strong></p><p dir="RTL">إذا كنت تعاني من حساسية لفول الصويا أو الفول السوداني، فلا تستخدم هذا المنتج الدوائي.</p><p dir="RTL">يحتوى سيلسنترى على أقل من واحد ملى مول من الصوديم (23 ملجم) لكل قرص، مما يعني أنه فى الأساس &nbsp;&quot;خالى من الصوديم&quot;.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب الالتزام الدائم بدقة بتعليمات الطبيب بشأن طريقة تناول أو إعطاء هذا الدواء. راجع الطبيب أو الصيدلي لديك في حالة عدم التأكد من ذلك.</p><p dir="RTL">سيخبرك طبيبك بما إذا كان من الأفضل أخذ محلول &rlm;‫سيلسينتري المخصص للتناول عن طريق الفم إذا كنت غير قادر على ابتلاع الأقراص.</p><p dir="RTL"><strong>الجرعة</strong></p><p dir="RTL"><strong>البالغون</strong></p><p dir="RTL"><strong>الجرعة الموصى بها من سيلسينتري<sup> </sup>هي </strong><strong>150</strong><strong>&nbsp;ملجم أو </strong><strong>300</strong><strong>&nbsp;ملجم أو </strong><strong>600</strong><strong>&nbsp;ملجم مرتان يوميًا</strong> حسب الأدوية الأخرى التي تتناولها في الوقت نفسه. التزم دائمًا بالجرعة التي أوصى بها الطبيب.</p><p dir="RTL"><strong>&nbsp;الأشخاص المصابون بمشاكل الكلى </strong></p><p dir="RTL">إذا كنت تعاني من مشكلة في الكلى، فربما يعدّل الطبيب الجرعة.</p><p dir="RTL">&ccedil;&nbsp; <strong>تحدث إلى الطبيب</strong> &lrm;إذا كانت هذه الحالة تنطبق عليك.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>يمكن تناول سيلسينتري مع الطعام أو دونه.</strong> يجب تناول سيلسينتري عن طريق الفم دائمًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يجب تناول سيلسينتري مع الأدوية الأخرى التي تُستخدَم لعلاج فيروس نقص المناعة البشرية. راجع نشرات العبوات الخاصة بهذه الأدوية الأخرى لمعرفة إرشادات حول كيفية تناول هذه الأدوية.</p><p dir="RTL">في حالة تناول أو إعطاء جرعة زائدة من سيلسينتري<!--[if supportFields]><span lang=AR-SA
style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='mso-bidi-font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif;mso-bidi-font-weight:bold'><span dir=RTL></span><span
dir=RTL></span> </span><span dir=LTR style='mso-bidi-font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;mso-bidi-font-weight:bold'>VAULT_ND_f6124228-5784-4236-9436-b2709d8d93c3
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">إذا تناولت أو أعطيت جرعة مفرطة من سيلسينتري دون قصد،</p><p dir="RTL"><strong>&ccedil;&nbsp;&nbsp;&nbsp; </strong><strong>فاتصل بالطبيب أو توجّه إلى أقرب مستشفى على الفور.</strong></p><p dir="RTL"><strong>في حال نسيان تناول أو إعطاء سيلسينتري</strong><!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='mso-bidi-font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif;mso-bidi-font-weight:bold'><span dir=RTL></span><span
dir=RTL></span> </span><span dir=LTR style='mso-bidi-font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;mso-bidi-font-weight:bold'>VAULT_ND_03833988-93d9-4f0a-9875-31f1ffc95f80
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">إذا فاتتك جرعة من سيلسينتري، فتناول أو أعطي الجرعة الفائتة في أقرب وقت ممكن، وبعد ذلك تابع الجرعة التالية في<br />وقتها المعتاد.</p><p dir="RTL">إذا كان وقت الجرعة التالية قريبًا جدًا، فلا تتناول أو تعطي الجرعة الفائتة. يجب عليك الانتظار وتناول الجرعة التالية في<br />وقتها المعتاد.</p><p dir="RTL"><strong>ولا يجوز تناول أو </strong><strong>إ</strong><strong>عطاء جرعة مضاعفة لتعويض الجرعة الفائتة.&rlm;</strong>‫</p><p dir="RTL"><strong>في حالة توقفك عن تناول سيلسينتري</strong><!--[if supportFields]><span lang=AR-SA
style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span style='mso-element:field-begin'></span> </span><span
dir=LTR style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'>DOCVARIABLE</span><span dir=RTL></span><span
dir=RTL></span><span style='mso-bidi-font-size:11.0pt;line-height:115%;
font-family:"Arial",sans-serif;mso-bidi-font-weight:bold'><span dir=RTL></span><span
dir=RTL></span> </span><span dir=LTR style='mso-bidi-font-size:11.0pt;
line-height:115%;font-family:"Arial",sans-serif;mso-bidi-font-weight:bold'>VAULT_ND_2083003c-6da5-49cb-a9a0-d12d6cf25485
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span dir=RTL></span><span dir=RTL></span> <span
lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='mso-bidi-font-size:11.0pt;line-height:115%;font-family:"Arial",sans-serif;
mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p><p dir="RTL">واصل تناول سيلسينتري إلى أن يوجهك الطبيب بالتوقف.</p><p dir="RTL">يُعتبَر تناول الأدوية في الوقت المناسب كل يوم أمرًا مهمًا لأن ذلك يضمن عدم زيادة العدوى بفيروس نقص المناعة البشرية في جسمك. ولذلك، من المهم أن تستمر في تناول سيلسينتري بشكل صحيح على النحو الموضح أعلاه ما لم ينصحك الطبيب بالتوقف عن العلاج.&nbsp;</p><p dir="RTL">إذا كانت لديك أي أسئلة إضافية حول استعمال هذا الدواء، يمكنك سؤال الطبيب أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يمكن أن يتسبب هذا الدواء، مثل جميع الأدوية، في حدوث آثار جانبية، لكن ليس بالضرورة أن يصاب بها جميع الأشخاص.<br />أبلغ الطبيب عند ملاحظة أي شيء غير معتاد بشأن صحتك.</p><p><strong>الآثار الجانبية الخطيرة - احصل على المساعدة الطبية فورًا<!--[if supportFields]><span
lang=AR-SA style='font-size:11.0pt;line-height:115%'><span style='mso-element:
field-begin'></span> </span><span dir=LTR style='font-size:11.0pt;line-height:
115%'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
style='font-size:11.0pt;line-height:115%'><span dir=RTL></span><span dir=RTL></span>
</span><span dir=LTR style='font-size:11.0pt;line-height:115%'>VAULT_ND_73df9453-531b-4bf2-95a6-2848c8c3bdf2
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='font-size:11.0pt;line-height:115%'><span dir=RTL></span><span dir=RTL></span>
<span lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;</strong><!--[if supportFields]><span
lang=AR-SA style='font-size:11.0pt;line-height:115%'><span style='mso-element:
field-end'></span></span><![endif]--></p><p><strong>التفاعلات الجلدية أو التحسسية الشديدة<!--[if supportFields]><span lang=AR-SA
style='font-size:11.0pt;line-height:115%'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='font-size:11.0pt;line-height:115%'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='font-size:11.0pt;line-height:
115%'><span dir=RTL></span><span dir=RTL></span> </span><span dir=LTR
style='font-size:11.0pt;line-height:115%'>VAULT_ND_d2f1c2aa-4fdd-457e-9bd7-7cd0f2eaddef
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='font-size:11.0pt;line-height:115%'><span dir=RTL></span><span dir=RTL></span>
<span lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;</strong><!--[if supportFields]><span
lang=AR-SA style='font-size:11.0pt;line-height:115%'><span style='mso-element:
field-end'></span></span><![endif]--></p><p dir="RTL">أصيب بعض الأشخاص الذين يتناولون سيلسينتري بتفاعلات تحسسية وجلدية حادة ومهددة للحياة. هذه المشاكل نادرة ويمكن أن تصيب شخصًا واحدًا بحد أقصى من بين كل 1000 شخص يتناولون سيلسينتري.</p><p dir="RTL">في حالة ظهور أي من الأعراض التالية أثناء تناول سيلسينتري:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورّم الوجه أو الشفتين أو اللسان</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي واسع الانتشار</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى (ارتفاع درجة الحرارة)</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تقرّحات وتقشير في الجلد، خاصةً حول الفم والأنف والعينين والأعضاء التناسلية.</p><p dir="RTL"><strong>&ccedil;&nbsp; </strong><strong>احصل على مساعدة طبية على الفور</strong> إذا أصابتك هذه الأعراض. <strong>وتوقف عن تناول سيلسينتري.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>مشاكل الكبد </strong></p><p dir="RTL">هذه المشاكل نادرة ويمكن أن تصيب شخصًا واحدًا بحد أقصى من بين كل 1000 شخص يتناولون سيلسينتري.</p><p dir="RTL">تشمل العلامات:</p><ul><li dir="RTL">فقدان الشهية</li><li dir="RTL">الشعور بالغثيان أو القيء</li><li dir="RTL">اصفرار الجلد أو العينين</li></ul><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ظهور طفح جلدي أو الإحساس بحكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالإرهاق الشديد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم أو توجّع بالمعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لون بول داكن</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النعاس والتشوش</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحمى (ارتفاع درجة الحرارة).</p><p dir="RTL"><strong>&ccedil;&nbsp;&nbsp;&nbsp; </strong><strong>اتصل بطبيب على الفور</strong> إذا أصابتك هذه الأعراض. <strong>وتوقف عن تناول سيلسينتري.</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية الأخرى</strong></p><p dir="RTL"><strong>الآثار الجانبية الشائعة </strong></p><p dir="RTL">يمكن أن تصيب هذه الآثار <strong>من شخص إلى 10 بين كل </strong><strong>100</strong><strong> شخص</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال، والشعور بالغثيان، وألم المعدة، والانتفاخ بسبب الغازات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع، ومشاكل النوم، والاكتئاب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي <em>(راجع أيضًا &quot;التفاعلات الجلدية أو التحسسية الشديدة&quot; سابقًا في القسم </em><em>4</em><em>)</em></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &rlm;‫الشعور بالضعف أو فقدان الطاقة، وفقر الدم (لوحظ ذلك في نتيجة فحص الدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة إنزيمات الكبد (لوحظ ذلك في نتائج فحوصات الدم)، ويمكن أن تكون علامة على مشاكل في الكبد (<em>راجع أيضًا &quot;مشاكل الكبد&quot; سابقًا في القسم </em><em>4</em>).</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية غير الشائعة </strong></p><p dir="RTL">قد تصيب <strong>واحدًا بحد أقصى من بين كل </strong><strong>100</strong><strong> شخص</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الالتهاب الرئوي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العدوى الفطرية في المريء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; النوبات <em>(التشنجات)</em>.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الشعور بالدوار أو الإغماء أو الدوخة عند الوقوف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الفشل الكلوي، وإفراز البروتين في البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة في مادة تُعرَف باسم CPK (لوحظ ذلك في نتائج فحوصات الدم) والتي تكون علامة على التهاب أو تلف العضلات</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الآثار الجانبية النادرة </strong></p><p dir="RTL">قد تصيب<strong> واحدًا بحد أقصى من بين كل </strong><strong>1000</strong><strong> شخص</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الصدر (ينتج عن انخفاض تدفق الدم إلى القلب).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص في حجم العضلة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض أنواع السرطان، مثل سرطان المريء وتقلص القناة الصفراوية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; نقص في عدد خلايا الدم (لوحظ ذلك في نتائج فحوصات الدم).</p><p dir="RTL"><strong>الآثار الجانبية الأخرى المحتملة للعلاج المركب لفيروس نقص المناعة البشرية</strong></p><p dir="RTL">قد يتعرض المرضى الذين يتناولون علاجًا مركبًا لفيروس نقص المناعة البشرية إلى آثار جانبية أخرى.</p><p>أعراض العدوى والالتهاب<!--[if supportFields]><span
lang=AR-SA style='font-size:11.0pt;line-height:115%'><span style='mso-element:
field-begin'></span> </span><span dir=LTR style='font-size:11.0pt;line-height:
115%'>DOCVARIABLE</span><span dir=RTL></span><span dir=RTL></span><span
style='font-size:11.0pt;line-height:115%'><span dir=RTL></span><span dir=RTL></span>
</span><span dir=LTR style='font-size:11.0pt;line-height:115%'>VAULT_ND_5d926943-b491-4b3f-a5b4-00fc0c873ab1
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='font-size:11.0pt;line-height:115%'><span dir=RTL></span><span dir=RTL></span>
<span lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
lang=AR-SA style='font-size:11.0pt;line-height:115%'><span style='mso-element:
field-end'></span></span><![endif]--></p><p dir="RTL">يعاني المرضى المصابون بحالة متقدمة من عدوى نقص المناعة البشرية (الإيدز) من ضعف الجهاز المناعي، ويصبحون أكثر عرضة للإصابة بحالات عدوى خطيرة (حالات العدوى الانتهازية). وعندما يبدأون العلاج، يقوى الجهاز المناعي ويبدأ الجسم في محاربة العدوى.</p><p dir="RTL"><strong>قد تظهر أعراض العدوى والالتهاب ويكون السبب فيها إما:</strong></p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى قديمة مستترة تنشط مرة أخرى حين يحاربها الجسم</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مهاجمة الجهاز المناعي لأنسجة الجسم السليمة (اضطرابات المناعة الذاتية).</p><p dir="RTL"><strong>وربما تظهر أعراض اضطرابات المناعة الذاتية</strong> بعد أشهر من بدء تناول الدواء لعلاج عدوى فيروس نقص المناعة البشرية. قد تشمل الأعراض:</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف العضلات</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف يبدأ في اليدين والقدمين وينتقل لأعلى باتجاه جذع الجسم</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حالات خفقان القلب أو الرعاش</p><p dir="RTL">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فرط الحركة (التململ والحركة الزائدة).</p><p dir="RTL">إذا أصابك أي من أعراض العدوى، أو لاحظت أيًا من الأعراض المذكورة أعلاه:</p><p dir="RTL">&ccedil;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>فأخبر طبيبك فورًا.</strong> ولا تتناول أي أدوية أخرى لعلاج العدوى دون استشارة الطبيب.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>تيبس وألم في المفاصل ومشاكل في العظام</strong></p><p dir="RTL">يصاب بعض الأشخاص الذين يتناولون العلاج المركب لفيروس نقص المناعة البشرية بحالة يُطلَق عليها <em>النخر العظمي</em>.<br />في هذه الحالة، تموت أجزاء من أنسجة العظام بسبب انخفاض تدفق الدم إلى العظام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مدى شيوع هذه الحالة غير معروف. وقد تصبح أكثر عرضة للإصابة بها إذا كنت تتناول علاجًا مركبًا لفترة طويلة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول الأدوية المضادة للالتهابات التي يُطلَق عليها الكورتيكوستيرويدات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تتناول مشروبات كحولية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من ضعف شديد في الجهاز المناعي</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من زيادة الوزن</p><p><strong>تتضمن العلامات التي ينبغي الانتباه لها ما يلي:<!--[if supportFields]><span lang=AR-SA
style='font-size:11.0pt;line-height:115%'><span style='mso-element:field-begin'></span>
</span><span dir=LTR style='font-size:11.0pt;line-height:115%'>DOCVARIABLE</span><span
dir=RTL></span><span dir=RTL></span><span style='font-size:11.0pt;line-height:
115%'><span dir=RTL></span><span dir=RTL></span> </span><span dir=LTR
style='font-size:11.0pt;line-height:115%'>VAULT_ND_50b52ecb-e9a9-43a7-bb6f-4b40eac41eb8
\* MERGEFORMAT</span><span dir=RTL></span><span dir=RTL></span><span
style='font-size:11.0pt;line-height:115%'><span dir=RTL></span><span dir=RTL></span>
<span lang=AR-SA><span style='mso-element:field-separator'></span></span></span><![endif]-->&nbsp;</strong><!--[if supportFields]><span
lang=AR-SA style='font-size:11.0pt;line-height:115%'><span style='mso-element:
field-end'></span></span><![endif]--></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تيبس المفاصل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أوجاع وآلام (وخاصة في الورك أو الركبة أو الكتف)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة الحركة</p><p dir="RTL">عند ملاحظة أي من هذه الأعراض:</p><p dir="RTL">&nbsp;&ccedil;<strong>أخبر</strong> <strong>طبيبك</strong>.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يجب حفظه بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">تجنّب استخدام سيلسينتري بعد تاريخ انتهاء الصلاحية المذكور على ملصق العبوة الكرتونية أو الشريط أو الزجاجة. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من الشهر المذكور.</p><p dir="RTL">يجب عدم تخزين سيلسينتري في درجة حرارة أعلى من 30 درجة مئوية.</p><p dir="RTL">&rlm;‫لا تتخلص من أي أدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. يجب سؤال الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. &rlm;‫فهذه الإجراءات من شأنها المساعدة على حماية البيئة.&rlm;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المادة الفعَّالة في سيلسينتري هي مارافايروك. يحتوي كل قرص مُغلَّف على إما 150&nbsp;ملجم أو 300&nbsp;ملجم من مارافايروك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أما المكوّنات الأخرى فهي:</p><p dir="RTL"><u>لب القرص:</u> سليلوز دقيق التبلور، فوسفات كالسيوم هيدروجيني لا مائي، جلايكولات نشاء الصوديوم، سترات الماغنسيوم</p><p dir="RTL"><u>غلاف القرص:</u> بولي (كحول الفينيل)، ثاني أكسيد التيتانيوم، ماكروغول 3350، التلك، ليسيثين الصويا، صبغة ألومنيوم ليك باللون القرمزي النيلي (E132)</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">أقراص سيلسينتري المغلَّفة ذات لون أزرق ومكتوب عليها &quot;MVC 150&quot; أو &quot;MVC 300&quot;.</p><p dir="RTL">تتوفر أقراص سيلسينتري المغلَّفة 150 ملجم و300 ملجم في زجاجات تحتوي على 180 قرصًا أو في شرائط فقاعية تحتوي على 30 أو 60 أو 90 قرصًا مغلَّفًا وعبوات متعددة تحتوي على 180 قرصًا مغلَّفًا (عبوتان تحتوي كل منهما على 90 قرصًا مغلَّفًا).</p><p dir="RTL">قد لا تتوفر بعض أحجام العبوات في أسواق بعض البلدان.</p><p dir="RTL"><strong>سيلسينتري</strong> علامة تجارية مملوكة أو مرخصة لمجموعة شركات ڤیڤ هيلثكير.</p><p dir="RTL">&copy;2023 مجموعة شركات ڤیڤ هيلثكير. جميع الحقوق محفوظة.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>الشركة المُصنّعة:</strong></p><p dir="RTL">Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg, Mooswaldallee 1,79090 Freiburg, Germany</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>مالك التسويق المعتمد </strong></p><p dir="RTL">جلاكسو العربية السعودية المحدودة*، جدة، المملكة العربية السعودية</p><p dir="RTL">*عضو مجموعة شركات جلاكسو سميث كلاين</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            رقم الإصدار: EMAv13
تاريخ الإصدار:19 أغسطس 2022 
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                 CELSENTRI 150 mg & 300 mg film-coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CELSENTRI 150 mg film-coated tablets

Each film-coated tablet contains 150 mg of maraviroc. 
Excipient with known effect: each 150 mg film-coated tablet contains 0.84 mg of soya lecithin.

CELSENTRI 300 mg film-coated tablets

Each film-coated tablet contains 300 mg of maraviroc.
Excipient with known effect: each 300 mg film-coated tablet contains 1.68 mg of soya lecithin. 

For the full list of excipients, see section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablet. 

CELSENTRI 150 mg film-coated tablets
Blue, biconvex, oval film-coated tablets, approximate dimensions 8.56 mm x 15.5 mm and debossed with “MVC 150” 
 
CELSENTRI 300 mg film-coated tablets
Blue, biconvex, oval film-coated tablets, approximate dimensions 10.5 mm x 19.0 mm and debossed with “MVC 300”.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>CELSENTRI, in combination with other antiretroviral medicinal products, is indicated for treatment-experienced adults infected with only CCR5-tropic HIV-1 detectable (see sections 4.2 and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Therapy should be initiated by a physician experienced in the management of HIV infection.</p><p><u>Posology</u></p><p>Before taking CELSENTRI it has to be confirmed that only CCR5-tropic HIV-1 is detectable (i.e. CXCR4 or dual/mixed tropic virus not detected) using an adequately validated and sensitive detection method on a newly drawn blood sample. The Monogram Trofile assay was used in the clinical studies of CELSENTRI (see sections 4.4 and 5.1). The viral tropism cannot be safely predicted by treatment history and assessment of stored samples.</p><p>There are currently no data regarding the reuse of CELSENTRI in patients that currently have only CCR5-tropic HIV-1 detectable, but have a history of failure on CELSENTRI (or other CCR5 antagonists) with a CXCR4 or dual/mixed tropic virus. There are no data regarding the switch from a medicinal product of a different antiretroviral class to CELSENTRI in virologically suppressed patients. Alternative treatment options should be considered.&nbsp;&nbsp;</p><p><u>Adults: </u></p><p>The recommended dose of CELSENTRI is 150 mg, (with potent CYP3A inhibitor with or without a potent CYP3A inducer), 300&nbsp;mg (without potent CYP3A inhibitors or inducers) or 600 mg twice daily (with potent CYP3A inducer without a potent CYP3A inhibitor) depending on interactions with concomitant antiretroviral therapy and other medicinal products (see&nbsp; section 4.5).</p><p>The recommended dose of CELSENTRI differs depending on interactions with concomitant antiretroviral therapy and other medicinal products. Refer to section 4.5 for corresponding adult dosage.</p><p>Many medicines have profound effects on maraviroc exposure due to drug-drug interactions. Prior to deciding the dose of CELSENTRI by weight, please refer to Table 2 in section 4.5 to carefully determine the corresponding adult dose. The corresponding paediatric dose can then be obtained from Table 1 below. If uncertainty still exists, contact a pharmacist for advice.</p><p>&nbsp;</p><p>Table 1 Recommended dosing regimen</p><table border="0" cellspacing="0" cellpadding="0" style="width:100%"><tbody><tr><td rowspan="2"><p><strong>Adult dosage*</strong></p></td><td rowspan="2"><p><strong>Concomitant Medications</strong></p></td><td>&nbsp;</td></tr><tr><td>&nbsp;</td></tr><tr><td><p>150 mg twice daily</p></td><td><p>celsentri with products that are potent CYP3A inhibitors (with or without a CYP3A inducer)</p></td><td>&nbsp;</td></tr><tr><td><p>300 mg twice daily</p></td><td><p>celsentri with products that are not potent CYP3A inhibitors or potent CYP3A inducers</p></td><td>&nbsp;</td></tr><tr><td><p>600 mg twice daily</p></td><td><p>celsentri with products that are CYP3A inducers (without a potent CYP3A inhibitor)</p></td><td>&nbsp;</td></tr></tbody></table><p>* Based on drug-drug Interactions (refer to section 4.5)</p><p><u>Special populations</u></p><p><u>Elderly </u></p><p>There is limited experience in patients &gt;65 years of age (see section 5.2), therefore CELSENTRI should be used with caution in this population.</p><p><u>Renal impairment </u></p><p>In adult patients with a creatinine clearance of &lt;80 mL/min, who are also receiving potent CYP3A4 inhibitors, the dose interval of maraviroc should be adjusted to 150 mg <u>once</u> daily (see sections 4.4 and 4.5).&nbsp;</p><p>&nbsp;</p><p>Examples of agents/regimens with such potent CYP3A4-inhibiting activity are:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ritonavir-boosted protease inhibitors (with the exception of tipranavir/ritonavir),</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cobicistat,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; itraconazole, voriconazole, clarithromycin and telithromycin,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; telaprevir and boceprevir.</p><p>&nbsp;</p><p>CELSENTRI should be used with caution in adult patients with severe renal impairment</p><p>(CLcr &lt;30 mL/min) who are receiving potent CYP3A4 inhibitors&nbsp;(see sections 4.4 and 5.2).</p><p>There are no data available to recommend a specific dose in paediatric patients with renal impairment. Therefore, CELSENTRI should be used with caution in this population.</p><p><u>Hepatic impairment</u></p><p>Limited data are available in adult patients with hepatic impairment, and no data are available to recommend a specific dose for paediatric patients. &nbsp;Therefore, CELSENTRI should be used with caution in patients with hepatic impairment (see sections 4.4 and 5.2).</p><p><u>Method of administration</u></p><p>Oral use.</p><p>CELSENTRI can be taken with or without food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to peanut or soya or to any of the excipients listed in section 6.1.

Contraindicated in patients with severe renal impairment or ESRD (CrCl less than 30 mL per minute) who are concomitantly taking potent CYP3A inhibitors or inducers.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Hepatic disease &nbsp;</u></p><p>The safety and efficacy of maraviroc have not been specifically studied in patients with significant underlying liver disorders.</p><p>Cases of hepatotoxicity and hepatic failure with allergic features have been reported in association with maraviroc.&nbsp;In addition, an increase in hepatic adverse reactions with maraviroc was observed during studies of treatment-experienced subjects with HIV infection, although there was no overall increase in ACTG Grade 3/4 liver function test abnormalities (see section 4.8). Hepatobiliary disorders reported in treatment na&iuml;ve patients were uncommon and balanced between treatment groups (see section 4.8). Patients with pre-existing liver dysfunction, including chronic active hepatitis, can have an increased frequency of liver function abnormalities during combination antiretroviral therapy and should be monitored according to standard practice.</p><p>Discontinuation of maraviroc should be strongly considered in any patient with signs or symptoms of acute hepatitis, in particular if drug-related hypersensitivity is suspected or with increased liver transaminases combined with rash or other systemic symptoms of potential hypersensitivity (e.g. pruritic rash, eosinophilia or elevated IgE).</p><p>There are limited data in patients with hepatitis B and/or C virus co-infection (see section 5.1). Caution should be exercised when treating these patients. In case of concomitant antiviral therapy for hepatitis B and/or C, please refer to the relevant product information for these medicinal products.</p><p>There is limited experience in patients with reduced hepatic function, therefore maraviroc should be used with caution in this population (see sections 4.2 and 5.2).</p><p><u>Severe skin and hypersensitivity reactions </u></p><p>Hypersensitivity reactions including severe and potentially life threatening events have been reported in patients taking CELSENTRI, in most cases concomitantly with other medicinal products associated with these reactions. These reactions included rash, fever, and sometimes organ dysfunction and hepatic failure. Discontinue CELSENTRI and other suspect agents immediately if signs or symptoms of severe skin or hypersensitivity reactions develop. Clinical status and relevant blood chemistry should be monitored and appropriate symptomatic therapy initiated.</p><p><u>Cardiovascular safety </u></p><p>Limited data exist with the use of maraviroc in patients with severe cardiovascular disease, therefore special caution should be exercised when treating these patients with maraviroc. In the pivotal studies of treatment experienced patients coronary heart disease events were more common in patients treated with maraviroc than with placebo (11 during 609 PY vs 0 during 111 PY of follow-up). In treatment na&iuml;ve patients such events occurred at a similarly low rate with maraviroc and control (efavirenz).</p><p><u>Postural hypotension</u></p><p>When maraviroc was administered in studies with healthy volunteers at doses higher than the recommended dose, cases of symptomatic postural hypotension were seen at a greater frequency than with placebo. Caution should be used when administering maraviroc in patients on concomitant medicinal products known to lower blood pressure.&nbsp; Maraviroc should also be used with caution in patients with severe renal insufficiency and in patients who have risk factors for, or have a history of postural hypotension.&nbsp; Patients with cardiovascular co-morbidities could be at increased risk of cardiovascular adverse reactions triggered by postural hypotension.</p><p><u>Renal impairment</u></p><p>An increased risk of postural hypotension may occur in patients with severe renal insufficiency who are treated with potent CYP3A inhibitors or boosted protease inhibitors (PIs) and maraviroc. This risk is due to potential increases in maraviroc maximum concentrations when maraviroc is co-administered with potent CYP3A inhibitors or boosted PIs in these patients.</p><p><u>Immune reconstitution syndrome</u></p><p>In HIV infected patients with severe immune deficiency at the time of institution of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic pathogens may arise and cause serious clinical conditions, or aggravation of symptoms. Typically, such reactions have been observed within the first few weeks or months of initiation of CART. Relevant examples are cytomegalovirus retinitis, generalised and/or focal mycobacterial infections, and pneumonia caused by<strong><em> </em></strong><em>Pneumocystis jiroveci </em>(formerly known as<strong><em> </em></strong><em>Pneumocystis carinii</em>). Any inflammatory symptoms should be evaluated and treatment initiated when necessary. Autoimmune disorders (such as Graves&rsquo; disease and autoimmune hepatitis) have also been reported to occur in the setting of immune reactivation; however, the reported time to onset is more variable and these events can occur many months after initiation of treatment.</p><p><u>Tropism</u></p><p>Maraviroc should only be used when only CCR5-tropic HIV-1 is detectable (i.e. CXCR4 or dual/mixed tropic virus not detected) as determined by an adequately validated and sensitive detection method (see sections 4.1, 4.2 and 5.1). The Monogram Trofile assay was used in the clinical studies of maraviroc. The viral tropism cannot be predicted by treatment history or assessment of stored samples.</p><p>Changes in viral tropism&nbsp;occur over time in HIV-1 infected patients. Therefore there is a need to start therapy&nbsp;shortly after&nbsp;a tropism test.</p><p>Background resistance to other classes of antiretrovirals have been shown to be similar in previously undetected CXCR4-tropic virus of the minor viral population, as that found in CCR5-tropic virus.</p><p><u>Maraviroc is not recommended to be used in treatment na&iuml;ve patients based on the results of a clinical study in this population (see section 5.1).</u></p><p>&nbsp;</p><p><u>Dose adjustment</u></p><p>Physicians should ensure that appropriate dose adjustment of maraviroc is made when maraviroc is co-administered with potent CYP3A4 inhibitors and/or inducers since maraviroc concentrations and its therapeutic effects may be affected (see sections 4.2 and 4.5). Please also refer to the respective Summary of Product Characteristics of the other antiretroviral medicinal products used in the combination.</p><p><u>Osteonecrosis</u></p><p><strong>&nbsp;</strong>Although the aetiology is considered to be multifactorial (including corticosteroid use, alcohol consumption, severe immunosuppression, higher body mass index), cases of osteonecrosis have been reported particularly in patients with advanced HIV-disease and/or long-term exposure to combination antiretroviral therapy (CART). Patients should be advised to seek medical advice if they experience joint aches and pain, joint stiffness or difficulty in movement.</p><p><u>Potential effect on immunity</u></p><p>CCR5 antagonists could potentially impair the immune response to certain infections. This should be taken into consideration when treating infections such as active tuberculosis and invasive fungal infections. The incidence of AIDS-defining infections was similar between CELSENTRI and placebo arms in the pivotal studies.</p><p><u>Excipients</u></p><p>CELSENTRI contains soya lecithin.</p><p>If a patient is hypersensitive to peanut or soya, CELSENTRI should not be used.</p><p>CELSENTRI contains less than 1&nbsp;mmol sodium (23&nbsp;mg) per tablet, that is to say essentially &lsquo;sodium free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Maraviroc is metabolised by cytochrome P450 CYP3A4 and CYP3A5. Co-administration of maraviroc with medicinal products that induce CYP3A4 may decrease maraviroc concentrations and reduce its therapeutic effects. Co-administration of maraviroc with medicinal products that inhibit CYP3A4 may increase maraviroc plasma concentrations. Dose adjustment of maraviroc is recommended when maraviroc is co-administered with potent CYP3A4 inhibitors and/or inducers. Further details for concomitantly administered medicinal products are provided below (see Table 2).&nbsp;</p><p>&nbsp;</p><p>Maraviroc is a substrate for the transporters P-glycoprotein and OATP1B1, but the effect of these transporters on the exposure to maraviroc is not known.</p><p>&nbsp;</p><p>Based on the <em>in vitro</em> and clinical data, the potential for maraviroc to affect the pharmacokinetics of co‑administered medicinal products is low. &nbsp;<em>In vitro </em>studies have shown that maraviroc does not inhibit any of the major P450 enzymes at clinically relevant concentrations (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4). Maraviroc had no clinically relevant effect on the pharmacokinetics of midazolam, the oral contraceptives ethinylestradiol and levonorgestrel, or urinary 6&beta;-hydroxycortisol/cortisol ratio, suggesting no inhibition or induction of CYP3A4 <em>in vivo</em>. At higher exposure of maraviroc a potential inhibition of CYP2D6 cannot be excluded.</p><p>&nbsp;</p><p>Renal clearance accounts for approximately 23% of total clearance of maraviroc when maraviroc is administered without CYP3A4 inhibitors. <em>In vitro</em> studies have shown that maraviroc does not inhibit OATP1B1, MRP2 or any of the major renal uptake transporters at clinically relevant concentrations (OAT1, OAT3, OCT2, OCTN1, and OCTN2). Additionally, co-administration of maraviroc with tenofovir (substrate for renal elimination) and cotrimoxazole (contains trimethoprim, a renal cation transport inhibitor), showed no effect on the pharmacokinetics of maraviroc. In addition, co-administration of maraviroc with lamivudine/zidovudine showed no effect of maraviroc on lamivudine (primarily renally cleared) or zidovudine (non-P450 metabolism and renal clearance) pharmacokinetics. Maraviroc inhibits P-glycoprotein <em>in vitro</em> (IC<sub>50</sub> is 183 &mu;M). However, maraviroc does not significantly affect the pharmacokinetics of digoxin <em>in vivo</em>. It may not be excluded that maraviroc can increase the exposure to the P-glycoprotein substrate dabigatran etexilate.</p><p>&nbsp;</p><p><strong>Table </strong><strong>2. Interactions and adult</strong><strong><sup>a</sup> dose recommendations with other medicinal products </strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:104%"><tbody><tr><td style="vertical-align:top"><p><strong>Medicinal product by therapeutic areas</strong></p><p><strong>(dose of CELSENTRI used in study)</strong></p></td><td style="vertical-align:top"><p><strong>Effects on active substance levels<br />Geometric mean change if not stated otherwise</strong></p></td><td style="vertical-align:top"><p><strong>Recommendations concerning co-administration in adults</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>ANTI-INFECTIVES</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong>Antiretrovirals</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Pharmacokinetic Enhancers</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Cobicistat</p></td><td style="vertical-align:top"><p>Interaction not studied.</p><p>&nbsp;</p><p>Cobicistat is a potent CYP3A inhibitor.</p></td><td style="vertical-align:top"><p>CELSENTRI dose should be decreased to 150 mg twice daily when co-administered with cobicistat containing regimen.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NRTIs)</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Lamivudine 150&nbsp;mg BID</p><p>(maraviroc 300&nbsp;mg BID)</p></td><td style="vertical-align:top"><p>Lamivudine&nbsp; AUC<sub>12</sub>: &harr; 1.13</p><p>Lamivudine&nbsp; C<sub>max</sub>: &harr; 1.16</p><p>Maraviroc concentrations not measured, no effect is expected.</p></td><td rowspan="3" style="vertical-align:top"><p>No significant interaction seen/expected. CELSENTRI 300 mg twice daily and NRTIs can be co-administered without dose adjustment.</p></td></tr><tr><td style="vertical-align:top"><p>Tenofovir 300&nbsp;mg QD</p><p>(maraviroc 300&nbsp;mg BID)</p></td><td style="vertical-align:top"><p>Maraviroc AUC<sub>12</sub>: &harr; 1.03</p><p>Maraviroc C<sub>max</sub>: &harr; 1.03</p><p>Tenofovir concentrations not measured, no effect is expected.</p></td></tr><tr><td style="vertical-align:top"><p>Zidovudine 300&nbsp;mg BID</p><p>(maraviroc 300&nbsp;mg BID)</p></td><td style="vertical-align:top"><p>Zidovudine AUC<sub>12</sub>: &harr; 0.98</p><p>Zidovudine C<sub>max</sub>: &harr; 0.92</p><p>Maraviroc concentrations not measured, no effect is expected.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Integrase Inhibitors</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Elvitegravir/ritonavir 150/100mg QD</p><p>(maraviroc 150 mg BID)</p></td><td style="vertical-align:top"><p>Maraviroc AUC<sub>12:</sub> &uarr; 2.86 (2.33‑3.51)</p><p>Maraviroc C<sub>max</sub>: &uarr; 2.15 (1.71‑2.69)</p><p>Maraviroc C<sub>12</sub>: &uarr; 4.23 (3.47‑5.16)</p><p>&nbsp;</p><p>Elvitegravir AUC<sub>24</sub>: &harr; 1.07 (0.96‑1.18)</p><p>Elvitegravir C<sub>max</sub>: &harr; 1.01 (0.89‑1.15)</p><p>Elvitegravir C<sub>24</sub>: &harr; 1.09 (0.95‑1.26)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>Elvitegravir as a single agent is indicated only in combination with certain ritonavir boosted PIs.</p><p>&nbsp;</p><p>Elvitegravir per se is not expected to affect maraviroc exposure to a clinically relevant degree and the observed effect is attributed to ritonavir.</p><p>&nbsp;</p><p>Thus, CELSENTRI dose should be modified in line with the recommendation for co-administration with respective PI/ritonavir combination (see &lsquo;Protease Inhibitors&rsquo;).</p></td></tr><tr><td style="vertical-align:top"><p>Raltegravir 400&nbsp;mg BID</p><p>(maraviroc 300&nbsp;mg BID)</p></td><td style="vertical-align:top"><p>Maraviroc AUC<sub>12</sub>: &darr; 0.86</p><p>Maraviroc C<sub>max</sub>: &darr; 0.79</p><p>&nbsp;</p><p>Raltegravir AUC<sub>12</sub>: &darr; 0.63</p><p>Raltegravir C<sub>max</sub>: &darr; 0.67</p><p>Raltegravir C<sub>12</sub>: &darr; 0.72</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>No clinically significant interaction seen. CELSENTRI 300 mg twice daily and raltegravir can be co-administered without dose adjustment.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>Non-Nucleoside Reverse Transcriptase Inhibitors (NNRTIs)</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Efavirenz 600&nbsp;mg QD</p><p>(maraviroc 100&nbsp;mg BID)</p></td><td style="vertical-align:top"><p>Maraviroc AUC<sub>12</sub>: &darr; 0.55</p><p>Maraviroc Cmax: &darr; 0.49</p><p>Efavirenz concentrations not measured, no effect is expected.</p></td><td style="vertical-align:top"><p>CELSENTRI dose should be increased to 600&nbsp;mg twice daily when co-administered with efavirenz in the absence of potent CYP3A4 inhibitor. For combination with efavirenz + PI, see separate recommendations below.</p></td></tr><tr><td style="vertical-align:top"><p>Etravirine 200 mg BID</p><p>(maraviroc 300&nbsp;mg BID)</p></td><td style="vertical-align:top"><p>Maraviroc AUC<sub>12</sub>: &darr; 0.47</p><p>Maraviroc C<sub>max</sub>: &darr; 0.40</p><p>&nbsp;</p><p>Etravirine AUC<sub>12</sub>: &harr; 1.06</p><p>Etravirine C<sub>max</sub>: &harr; 1.05</p><p>Etravirine C<sub>12</sub>: &harr; 1.08</p></td><td style="vertical-align:top"><p>Etravirine is only approved for use with boosted protease inhibitors. For combination with etravirine + PI, see below.</p></td></tr><tr><td style="vertical-align:top"><p>Nevirapine 200 mg BID</p><p>(maraviroc 300 mg Single Dose)</p></td><td style="vertical-align:top"><p>Maraviroc AUC<sub>12</sub>: &harr; compared to historical controls</p><p>Maraviroc C<sub>max</sub>: &uarr; compared to historical controls</p><p>Nevirapine concentrations not measured, no effect is expected.</p></td><td style="vertical-align:top"><p>Comparison to exposure in historical controls suggests that CELSENTRI 300 mg twice daily and nevirapine can be co-administered without dose adjustment.<s> </s></p></td></tr><tr><td style="vertical-align:top"><p><strong><em>&nbsp;Protease Inhibitors (PIs)</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Atazanavir 400&nbsp;mg QD</p><p>(maraviroc 300&nbsp;mg BID)</p></td><td style="vertical-align:top"><p>Maraviroc AUC<sub>12</sub> &uarr; 3.57</p><p>Maraviroc C<sub>max</sub>: &uarr; 2.09 Atazanavir concentrations not measured, no effect is expected.</p></td><td rowspan="7" style="vertical-align:top"><p>CELSENTRI dose should be decreased to 150&nbsp;mg twice daily when co-administered with a PI; except in combination with tipranavir/ritonavir where the CELSENTRI dose should be 300 mg BID.</p><p><s>&nbsp;</s></p></td></tr><tr><td style="vertical-align:top"><p>Atazanavir/ritonavir 300&nbsp;mg/100&nbsp;mg QD</p><p>(maraviroc 300&nbsp;mg BID)</p></td><td style="vertical-align:top"><p>Maraviroc AUC<sub>12</sub> &uarr; 4.88 Maraviroc C<sub>max</sub>: &uarr; 2.67 Atazanavir/ritonavir concentrations not measured, no effect is expected.</p></td></tr><tr><td style="vertical-align:top"><p>Lopinavir/ritonavir 400&nbsp;mg/100&nbsp;mg BID</p><p>(maraviroc 300&nbsp;mg BID)</p></td><td style="vertical-align:top"><p>Maraviroc AUC<sub>12</sub> &uarr; 3.95</p><p>Maraviroc C<sub>max</sub>: &uarr; 1.97 Lopinavir/ritonavir concentrations not measured, no effect is expected.</p></td></tr><tr><td style="vertical-align:top"><p>Saquinavir/ritonavir 1000&nbsp;mg/100&nbsp;mg BID</p><p>(maraviroc 100&nbsp;mg BID)</p></td><td style="vertical-align:top"><p>Maraviroc AUC<sub>12</sub> &uarr; 9.77</p><p>Maraviroc C<sub>max</sub>: &uarr; 4.78</p><p>Saquinavir/ritonavir concentrations not measured, no effect is expected.</p></td></tr><tr><td style="vertical-align:top"><p>Darunavir/ritonavir</p><p>600&nbsp;mg/100&nbsp;mg BID</p><p>(maraviroc 150&nbsp;mg BID)</p></td><td style="vertical-align:top"><p>Maraviroc AUC<sub>12</sub> &uarr; 4.05</p><p>Maraviroc C<sub>max</sub>: &uarr; 2.29 Darunavir/ritonavir concentrations were consistent with historical data.</p></td></tr><tr><td style="vertical-align:top"><p>Nelfinavir</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Limited data are available for co-administration with nelfinavir. Nelfinavir is a potent CYP3A4 inhibitor and would be expected to increase maraviroc concentrations.</p></td></tr><tr><td style="vertical-align:top"><p>Indinavir</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Limited data are available for co-administration with indinavir.&nbsp; Indinavir is a potent CYP3A4 inhibitor. Population PK analysis in phase 3 studies suggests dose reduction of maraviroc when co-administered with indinavir gives appropriate maraviroc exposure.</p></td></tr><tr><td style="vertical-align:top"><p>Tipranavir/ritonavir 500&nbsp;mg/200&nbsp;mg BID</p><p>(maraviroc 150&nbsp;mg BID)</p></td><td style="vertical-align:top"><p>Maraviroc AUC<sub>12</sub> &harr; 1.02</p><p>Maraviroc C<sub>max</sub>: &harr; 0.86</p><p>Tipranavir/ritonavir concentrations were consistent with historical data.</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Fosamprenavir/ritonavir</p><p>700&nbsp;mg/100&nbsp;mg&nbsp;BID</p><p>(maraviroc 300 mg&nbsp;BID)</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>Maraviroc AUC<sub>12:</sub> &uarr; 2.49</p><p>Maraviroc C<sub>max</sub>: &uarr; 1.52</p><p>Maraviroc C<sub>12</sub>: &uarr; 4.74</p><p>&nbsp;</p><p>Amprenavir AUC<sub>12</sub>: &darr; 0.65</p><p>Amprenavir C<sub>max</sub>: &darr; 0.66</p><p>Amprenavir C<sub>12</sub>: &darr; 0.64</p><p>&nbsp;</p><p>Ritonavir AUC<sub>12</sub>: &darr; 0.66</p><p>Ritonavir C<sub>max</sub>: &darr; 0.61</p><p>Ritonavir C<sub>12</sub>: &harr; 0.86</p></td><td style="vertical-align:top"><p>Concomitant use is not recommended. Significant reductions in amprenavir C<sub>min</sub> observed may result in virological failure in patients</p><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>NNRTI + PI</em></strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Efavirenz 600&nbsp;mg QD + lopinavir/ritonavir 400mg/100&nbsp;mg BID</p><p>(maraviroc 300&nbsp;mg BID)</p></td><td style="vertical-align:top"><p>Maraviroc AUC<sub>12:</sub> &uarr; 2.53 Maraviroc C<sub>max</sub>: &uarr; 1.25</p><p>Efavirenz, lopinavir/ritonavir concentrations not measured, no effect expected.</p></td><td rowspan="3" style="vertical-align:top"><p>CELSENTRI dose should be decreased to 150&nbsp;mg twice daily when co-administered with efavirenz and a PI (except tipranavir/ritonavir where the dose should be 600 mg twice daily).</p><p>Concomitant use of CELSENTRI and fosamprenavir/ritonavir is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Efavirenz 600&nbsp;mg QD + saquinavir/ritonavir 1000&nbsp;mg/100&nbsp;mg BID</p><p>(maraviroc 100&nbsp;mg BID)</p></td><td style="vertical-align:top"><p>Maraviroc AUC<sub>12:</sub> &uarr; 5.00</p><p>Maraviroc C<sub>max</sub>: &uarr; 2.26 Efavirenz, saquinavir/ritonavir concentrations not measured, no effect expected.</p></td></tr><tr><td style="vertical-align:top"><p>Efavirenz and<s> </s>atazanavir/ritonavir or darunavir/ritonavir</p></td><td style="vertical-align:top"><p>Not studied.&nbsp; Based on the extent of inhibition by atazanavir/ritonavir or darunavir/ritonavir in the absence of efavirenz, an increased exposure&nbsp; is expected.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Etravirine and<s> </s>darunavir/ritonavir</p><p>(maraviroc 150&nbsp;mg BID)</p></td><td style="vertical-align:top"><p>Maraviroc AUC<sub>12:</sub> &uarr; 3.10</p><p>Maraviroc C<sub>max</sub>: &uarr; 1.77</p><p>&nbsp;</p><p>Etravirine AUC<sub>12</sub>: &harr; 1.00</p><p>Etravirine C<sub>max</sub>: &harr; 1.08</p><p>Etravirine C<sub>12</sub>: &darr; 0.81</p><p>&nbsp;</p><p>Darunavir AUC<sub>12</sub>: &darr; 0.86</p><p>Darunavir C<sub>max</sub>: &harr; 0.96</p><p>Darunavir C<sub>12</sub>: &darr; 0.77</p><p>&nbsp;</p><p>Ritonavir AUC<sub>12</sub>: &harr; 0.93</p><p>Ritonavir C<sub>max</sub>: &harr; 1.02</p><p>Ritonavir C<sub>12</sub>: &darr; 0.74</p></td><td rowspan="2" style="vertical-align:top"><p>CELSENTRI dose should be decreased to 150&nbsp;mg twice daily when co-administered with etravirine and a&nbsp; PI</p><p>&nbsp;</p><p>&nbsp;</p><p>Concomitant use of CELSENTRI and fosamprenavir/ritonavir is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Etravirine and<s> </s>lopinavir/ritonavir, saquinavir/ritonavir or atazanavir/ritonavir</p></td><td style="vertical-align:top"><p>Not studied.&nbsp; Based on the extent of inhibition by lopinavir/ritonavir, saquinavir/ritonavir or atazanavir/ritonavir in the absence of etravirine, an increased exposure is expected.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>ANTIBIOTICS</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Sulphamethoxazole/ Trimethoprim 800&nbsp;mg/160&nbsp;mg BID</p><p>(maraviroc 300&nbsp;mg BID)</p></td><td style="vertical-align:top"><p>Maraviroc AUC<sub>12</sub>: &harr; 1.11</p><p>Maraviroc Cmax: &harr; 1.19</p><p>Sulphamethoxazole/trimethoprim concentrations not measured, no effect expected.</p></td><td style="vertical-align:top"><p>CELSENTRI 300 mg twice daily and sulphamethoxazole/trimethoprim can be co-administered without dose adjustment.</p></td></tr><tr><td style="vertical-align:top"><p>Rifampicin 600&nbsp;mg QD</p><p>(maraviroc 100&nbsp;mg BID)</p></td><td style="vertical-align:top"><p>Maraviroc AUC<sub>:</sub> &darr; 0.37</p><p>Maraviroc C<sub>max</sub>: &darr; 0.34</p><p>Rifampicin concentrations not measured, no effect expected.</p></td><td style="vertical-align:top"><p>CELSENTRI dose should be increased to 600&nbsp;mg twice daily when co-administered with rifampicin in the absence of a&nbsp; potent CYP3A4 inhibitor.&nbsp; This dose adjustment has not been studied in HIV patients. See also section 4.4.&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Rifampicin + efavirenz</p></td><td style="vertical-align:top"><p>Combination with two inducers has not been studied. There may be a risk of suboptimal levels with risk of loss of virologic response and resistance development.</p></td><td style="vertical-align:top"><p>Concomitant use of CELSENTRI and rifampicin + efavirenz is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Rifabutin + PI</p></td><td style="vertical-align:top"><p>Not studied. Rifabutin is considered to be a weaker inducer than rifampicin. When combining rifabutin with protease inhibitors that are potent inhibitors of CYP3A4 a net inhibitory effect on maraviroc is expected.</p></td><td style="vertical-align:top"><p>CELSENTRI dose should be decreased to 150&nbsp;mg twice daily when co-administered with rifabutin and a PI (except tipranavir/ritonavir where the dose should be 300 mg twice daily). See also section 4.4.</p><p>Concomitant use of CELSENTRI and fosamprenavir/ritonavir is not recommended.</p></td></tr><tr><td style="vertical-align:top"><p>Clarithromycin, Telithromycin</p></td><td style="vertical-align:top"><p>Not studied, but both are potent CYP3A4 inhibitors and would be expected to increase maraviroc concentrations.</p></td><td style="vertical-align:top"><p>CELSENTRI dose should be decreased to 150&nbsp;mg twice daily when co-administered with clarithromycin and telithromycin.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>ANTICONVULSANTS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Carbamezepine,</p><p>Phenobarbital,</p><p>Phenytoin</p></td><td style="vertical-align:top"><p>Not studied, but these are potent CYP3A4 inducers and would be expected to decrease maraviroc concentrations.</p></td><td style="vertical-align:top"><p>CELSENTRI dose should be increased to 600&nbsp;mg twice daily when co-administered with carbamazepine, phenobarbital or phenytoin in the absence of a potent CYP3A4 inhibitor.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>ANTIFUNGALS</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Ketoconazole 400&nbsp;mg QD (maraviroc 100&nbsp;mg BID)</p></td><td style="vertical-align:top"><p>Maraviroc AUC<sub>tau</sub>: &uarr; 5.00</p><p>Maraviroc C<sub>max</sub>: &uarr; 3.38 Ketoconazole concentrations not measured, no effect is expected.</p></td><td style="vertical-align:top"><p>CELSENTRI dose should be decreased to 150&nbsp;mg twice daily when co-administered with ketoconazole.</p></td></tr><tr><td style="vertical-align:top"><p>Itraconazole</p></td><td style="vertical-align:top"><p>Not studied.&nbsp; Itraconazole, is a potent CYP3A4 inhibitor and would be expected to increase the exposure of maraviroc.</p></td><td style="vertical-align:top"><p>CELSENTRI dose should be decreased to 150&nbsp;mg twice daily when co-administered with itraconazole.</p></td></tr><tr><td style="vertical-align:top"><p>Fluconazole</p></td><td style="vertical-align:top"><p>Fluconazole is considered to be a moderate CYP3A4 inhibitor. Population PK studies suggest that a dose adjustment of maraviroc is not required.</p></td><td style="vertical-align:top"><p>CELSENTRI 300 mg twice daily should be administered with caution when co-administered with fluconazole.</p></td></tr><tr><td style="vertical-align:top"><p><strong><em>ANTIVIRALS</em></strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Anti-HBV</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Pegylated interferon</p></td><td style="vertical-align:top"><p>Pegylated interferon has not been studied, no interaction is expected.</p></td><td style="vertical-align:top"><p>CELSENTRI 300 mg twice daily and pegylated interferon can be co‑administered without dose adjustment.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>Anti-HCV</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Ribavirin</p></td><td style="vertical-align:top"><p>Ribavirin has not been studied, no interaction is expected.</p></td><td style="vertical-align:top"><p>CELSENTRI 300 mg twice daily and ribavirin can be co‑administered without dose adjustment.</p></td></tr><tr><td style="vertical-align:top"><p><strong>DRUG ABUSE</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Methadone</p></td><td style="vertical-align:top"><p>Not studied, no interaction expected.</p></td><td style="vertical-align:top"><p>CELSENTRI 300 mg twice daily and methadone can be co-administered without dose adjustment.</p></td></tr><tr><td style="vertical-align:top"><p>Buprenorphine</p></td><td style="vertical-align:top"><p>Not studied, no interaction expected.</p></td><td style="vertical-align:top"><p>CELSENTRI 300 mg twice daily and buprenorphine can be co-administered without dose adjustment.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong>LIPID LOWERING </strong></p><p><strong>MEDICINAL PRODUCTS</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>S</strong><strong>tatins</strong></p></td><td style="vertical-align:top"><p>Not studied, no interaction expected.</p></td><td style="vertical-align:top"><p>CELSENTRI 300 mg twice daily and statins can be co-administered without dose adjustment.</p></td></tr><tr><td colspan="3" style="vertical-align:top"><p><strong><em>ANTIARRHYTHMICS</em></strong></p></td></tr><tr><td style="vertical-align:top"><p>Digoxin 0.25 mg</p><p>Single Dose</p><p>(maraviroc 300 mg BID)</p></td><td style="vertical-align:top"><p>Digoxin. AUC<sub>t:</sub> &harr; 1.00</p><p>Digoxin. C<sub>max</sub>: &harr; 1.04</p><p>Maraviroc concentrations not measured, no interaction expected.</p></td><td style="vertical-align:top"><p>CELSENTRI 300 mg twice daily and digoxin can be co‑administered without dose adjustment.</p><p>&nbsp;</p><p>The effect of maraviroc on digoxin at the dose of 600 mg BID has not been studied.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Oral contraceptives</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Ethinylestradiol 30&nbsp;mcg QD</p><p>(maraviroc 100&nbsp;mg BID)</p></td><td style="vertical-align:top"><p>Ethinylestradiol. AUC<sub>t:</sub> &harr; 1.00 Ethinylestradiol. C<sub>max</sub>: &harr; 0.99 Maraviroc concentrations not measured, no interaction expected.</p></td><td style="vertical-align:top"><p>CELSENTRI 300 mg twice daily. and ethinylestradiol can be co-administered without dose adjustment.</p></td></tr><tr><td style="vertical-align:top"><p>Levonorgestrel 150 mcg QD</p><p>(maraviroc 100&nbsp;mg BID)</p></td><td style="vertical-align:top"><p>Levonorgestrel. AUC<sub>12:</sub> &harr; 0.98</p><p>Levonorgestrel. C<sub>max</sub>: &harr; 1.01 Maraviroc concentrations not measured, no interaction expected.</p></td><td style="vertical-align:top"><p>CELSENTRI 300 mg twice daily and levonorgestrel can be co-administered without dose adjustment.</p></td></tr><tr><td style="vertical-align:top"><p><strong>Sedatives</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Benzodiazepines</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p>Midazolam 7.5&nbsp;mg Single Dose</p><p>(maraviroc 300&nbsp;mg BID)</p></td><td style="vertical-align:top"><p>Midazolam. AUC: &harr; 1.18</p><p>Midazolam. C<sub>max</sub>: &harr; 1.21</p><p>Maraviroc concentrations not measured, no interaction expected.</p></td><td style="vertical-align:top"><p>CELSENTRI 300 mg twice daily and midazolam can be co-administered without dose adjustment.</p></td></tr><tr><td style="vertical-align:top"><p><strong>HERBAL PRODUCTS</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>St John&rsquo;s Wort</strong></p><p><u>(Hypericum Perforatum)</u></p></td><td style="vertical-align:top"><p>Co-administration of maraviroc with St. John&#39;s Wort is expected to substantially decrease maraviroc concentrations and may result in suboptimal levels and lead to loss of virologic response and possible resistance to maraviroc.</p></td><td style="vertical-align:top"><p>Concomitant use of maraviroc and St. John&#39;s Wort&nbsp; or products containing St. John&#39;s Wort is not recommended.</p></td></tr></tbody></table><p><sup>a</sup> Refer to Table 1 for maraviroc paediatric dosing recommendations when co-administered with antiretroviral therapy and other medicinal products.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are limited data from the use of maraviroc in pregnant women. The effect of maraviroc on human pregnancy is unknown. Studies in animals showed reproductive toxicity at high exposures. Primary pharmacological activity (CCR5 receptor affinity) was limited in the species studied (see section 5.3). Maraviroc should be used during pregnancy only if the excepted benefit justifies the potential risk to the foetus.</p><p><u>Breast-feeding</u></p><p>It is unknown whether maraviroc is excreted in human milk. Available toxicological data in animals has shown extensive excretion of maraviroc in milk. Primary pharmacological activity (CCR5 receptor affinity) was limited in the species studied (see section 5.3).&nbsp; A risk to the newborn/infants cannot be excluded.&nbsp;</p><p>It is recommended that women living with HIV do not breast-feed their infants in order to avoid transmission of HIV.</p><p><u>Fertility</u></p><p>There is no data on the effects of maraviroc on human fertility. In rats, there were no adverse effects on male or female fertility (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Maraviroc may have a minor influence on the ability to drive and use machines. Patients should be informed that dizziness has been reported during treatment with maraviroc. The clinical status of the patient and the adverse reaction profile of maraviroc should be borne in mind when considering the patient&#39;s ability to drive, cycle or operate machinery.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p><em>Adults</em></p><p>Assessment of treatment related adverse reactions is based on pooled data from two Phase 2b/3 studies in treatment experienced adult patients (MOTIVATE 1 and MOTIVATE 2) and one study in treatment na&iuml;ve adult patients (MERIT) infected with CCR5-tropic HIV-1 (see sections 4.4 and 5.1).</p><p>&nbsp;</p><p>The most frequently reported adverse reactions occurring in the Phase 2b/3 studies were nausea, diarrhoea, fatigue and headache. These adverse reactions were common (&ge; 1/100 to &lt; 1/10).</p><p><u>Tabulated list of adverse reactions</u></p><p>The adverse reactions are listed by system organ class (SOC) and frequency. Within each frequency grouping, undesirable effects are presented in order of decreasing seriousness. Frequencies are defined as very common (&ge; 1/10), common (&ge; 1/100 to &lt; 1/10), uncommon (&ge;1/1000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000) , not known (cannot be estimated from the available data). The adverse reactions and laboratory abnormalities presented below are not exposure adjusted.</p><p>&nbsp;</p><p><strong>Table 3: Adverse reactions observed in clinical trials or post-marketing</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong><u>System Organ Class</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Adverse Reaction</u></strong></p></td><td style="vertical-align:top"><p><strong><u>Frequency</u></strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Pneumonia, oesophageal candidiasis</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Neoplasm benign, malignant and unspecified (including. cysts and polyps)</p></td><td style="vertical-align:top"><p>Bile duct cancer, diffuse large B-cell lymphoma, Hodgkin&rsquo;s disease, metastases to bone, metastases to liver, metastases to peritoneum, nasopharyngeal cancer, oesophageal carcinoma</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>Anaemia</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>Pancytopenia, granulocytopenia</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Depression, insomnia</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Seizures and seizure disorders</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Angina pectoris</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Postural hypotension (see section 4.4)</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p><p><u>&nbsp;</u></p></td><td style="vertical-align:top"><p>Abdominal pain, flatulence, &nbsp;nausea</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>common</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased; aspartate aminotransferase increased</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperbilirubinaemia, gamma-glutamyltransferase increased</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Hepatitis toxic, hepatic failure, hepatic cirrhosis, blood alkaline phosphatase increased</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td style="vertical-align:top"><p>Hepatic failure with allergic features</p></td><td style="vertical-align:top"><p>very rare</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>common</p></td></tr><tr><td style="vertical-align:top"><p>Stevens-Johnson syndrome / Toxic epidermal necrolysis</p></td><td style="vertical-align:top"><p>rare/ not known</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Myositis, blood creatine phosphokinase increased</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Muscle atrophy</p></td><td style="vertical-align:top"><p>rare</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Renal failure,&nbsp; proteinuria</p></td><td style="vertical-align:top"><p>uncommon</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>common</p></td></tr></tbody></table><p><em>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </em></p><p><u>Description of selected adverse reactions</u></p><p>Delayed type hypersensitivity reactions, typically occurring within 2-6 weeks after start of therapy and including rash, fever, eosinophilia and liver reactions have been reported (see also section 4.4). Skin and liver reactions can occur as single events, or in combination.</p><p>In HIV infected patients with severe immune deficiency at the time of initiation of combination antiretroviral therapy (CART), an inflammatory reaction to asymptomatic or residual opportunistic infections may arise. Autoimmune disorders (such as Graves&rsquo; disease and autoimmune hepatitis) have also been reported; however, the reported time to onset is more variable and these events<strong> </strong>can occur many months after initiation of treatment (see section 4.4).</p><p>Cases of osteonecrosis have been reported, particularly in patients with generally acknowledged risk factors, advanced HIV disease or long-term exposure to combination antiretroviral therapy (CART). The frequency of this is unknown (see section 4.4).</p><p>Cases of syncope caused by postural hypotension have been reported.</p><p>&nbsp;</p><p><u>Laboratory abnormalities</u></p><p>Table 4 shows the incidence &ge;1% of Grade 3-4 Abnormalities (ACTG Criteria) based on the maximum shift in laboratory test values without regard to baseline values.</p><p><strong>Table </strong><strong><u>4</u>: Incidence &ge;1% of grade 3-4 abnormalities (ACTG criteria) based on maximum shift in laboratory test values without regard to baseline studies MOTIVATE 1 and MOTIVATE 2 (pooled analysis, up to 48 weeks)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:571px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Laboratory parameter</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Limit</strong></p></td><td style="vertical-align:top"><p><strong>Maraviroc 300&nbsp;mg</strong></p><p><strong>twice daily </strong></p><p><strong>+ OBT</strong></p><p><strong>N =421</strong>*</p><p><strong>(%)</strong></p></td><td style="vertical-align:top"><p><strong>Placebo + OBT </strong></p><p><strong>&nbsp;</strong></p><p><strong>N =207</strong>*</p><p><strong>(%)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Aspartate aminotransferase</p></td><td style="vertical-align:top"><p>&gt;5.0x ULN</p></td><td style="vertical-align:top"><p>4.8</p></td><td style="vertical-align:top"><p>2.9</p></td></tr><tr><td style="vertical-align:top"><p>Alanine aminotransferase</p></td><td style="vertical-align:top"><p>&gt;5.0x ULN</p></td><td style="vertical-align:top"><p>2.6</p></td><td style="vertical-align:top"><p>3.4</p></td></tr><tr><td style="vertical-align:top"><p>Total bilirubin</p></td><td style="vertical-align:top"><p>&gt;5.0x ULN</p></td><td style="vertical-align:top"><p>5.5</p></td><td style="vertical-align:top"><p>5.3</p></td></tr><tr><td style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td colspan="3" style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Amylase</p></td><td style="vertical-align:top"><p>&gt;2.0x ULN</p></td><td style="vertical-align:top"><p>5.7</p></td><td style="vertical-align:top"><p>5.8</p></td></tr><tr><td style="vertical-align:top"><p>Lipase</p></td><td style="vertical-align:top"><p>&gt;2.0x ULN</p></td><td style="vertical-align:top"><p>4.9</p></td><td style="vertical-align:top"><p>6.3</p></td></tr><tr><td colspan="2" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p></td></tr><tr><td style="vertical-align:top"><p>Absolute neutrophil count</p></td><td style="vertical-align:top"><p>&lt;750/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>4.3</p></td><td style="vertical-align:top"><p>1.9</p></td></tr></tbody></table><p>ULN: Upper Limit of Normal</p><p>OBT: Optimised Background Therapy</p><p>* Percentages based on total patients evaluated for each laboratory parameter</p><p>&nbsp;</p><p>The MOTIVATE studies were extended beyond 96 weeks, with an observational phase extended to 5 years in order to assess the long term safety of maraviroc. The Long Term Safety/Selected Endpoints (LTS/SE) included death, AIDS-defining events, hepatic failure, Myocardial infarction/cardiac ischaemia, malignancies, rhabdomyolysis and other serious infectious events with maraviroc treatment.&nbsp; The incidence of these selected endpoints for subjects on maraviroc in this observational phase was consistent with the incidence seen at earlier timepoints in the studies.</p><p>In treatment-na&iuml;ve patients, the incidence of grade 3 and 4 laboratory abnormalities using ACTG criteria was similar among the <strong>maraviroc </strong>and efavirenz treatment groups.</p><p><u>Paediatric population</u></p><p>The adverse reaction profile in paediatric patients is based on 48 Week safety data from study A4001031 in which 103 HIV-1 infected, treatment-experienced patients aged 2 to 18 years received maraviroc twice-daily with optimised background therapy (OBT). Overall, the safety profile in paediatric patients was similar to that observed in adult clinical studies.</p><p>&nbsp;</p><p><strong>To report any side effect(s):</strong></p><p><strong><em>Kingdom of Saudi Arabia</em></strong></p><p><strong>-National Pharmacovigilance centre (NPC)</strong></p><ul><li>Reporting hotline: 19999</li><li>E-mail: npc.drug@sfda.gov.sa</li><li>Website: https://ade.sfda.gov.sa</li></ul><p><strong>-GSK - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: &nbsp;saudi.safety@gsk.com</li><li>website: https://gskpro.com/en-sa/</li><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul><p><strong>For any information about this medicinal product, please contact:</strong></p><p><strong>GSK - Head Office, Jeddah</strong></p><ul><li>Tel:&nbsp; +966-12-6536666</li><li>Mobile: +966-56-904-9882</li><li>Email: gcc.medinfo@gsk.com</li><li>Website: https://gskpro.com/en-sa/</li></ul><ul><li>P.O. Box 55850, Jeddah 21544, Saudi Arabia</li></ul>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>The highest dose administered in clinical studies was 1,200&nbsp;mg. The dose limiting adverse reaction was postural hypotension.</p><p>Prolongation of the QT interval was seen in dogs and monkeys at plasma concentrations 6 and 12 times, respectively, those expected in humans at the maximum recommended dose of 300&nbsp;mg twice daily.&nbsp;However, no clinically significant QT prolongation compared to placebo + OBT &nbsp;was seen in the Phase 3 clinical studies using the recommended dose of maraviroc or in a specific pharmacokinetic study to evaluate the potential of maraviroc &nbsp;to prolong the QT interval.</p><p><u>Management</u></p><p>There is no specific antidote for overdose with maraviroc. Treatment of overdose should consist of general supportive measures including keeping the patient in a supine position, careful assessment of patient vital signs, blood pressure and ECG.</p><p>If indicated, elimination of unabsorbed active maraviroc should be achieved by emesis or gastric lavage. Administration of activated charcoal may also be used to aid in removal of unabsorbed active substance. Since maraviroc is moderately protein bound, dialysis may be beneficial in removal of this medicine. Further management should be as recommended by the national poisons centre, where available.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Antivirals for systemic use, other antivirals, ATC code: J05AX09<!--[if supportFields]><span
style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_b6681751-eea3-492e-9d42-3a12a6a72fdd \* MERGEFORMAT <span
style='mso-element:field-separator'></span><![endif]-->&nbsp;<!--[if supportFields]><span style='mso-element:
field-end'></span><![endif]--></p><p><u>Mechanism of action</u></p><p>Maraviroc is a member of a therapeutic class called CCR5 antagonists. Maraviroc selectively binds to the human chemokine receptor CCR5, preventing CCR5-tropic HIV-1 from entering cells.</p><p><u>Antiviral activity in vitro</u></p><p>Maraviroc has no antiviral activity in vitro against viruses which can use CXCR4 as their entry co-receptor (dual-tropic or CXCR4-tropic viruses, collectively termed &lsquo;CXCR4-using&rsquo; virus below). The serum adjusted EC90 value in 43 primary HIV-1 clinical isolates was 0.57 (0.06 &ndash; 10.7) ng/mL without significant changes between different subtypes tested.&nbsp; The antiviral activity of maraviroc against HIV-2 has not been evaluated. For details please refer to the pharmacology section of the CELSENTRI European Public Assessment Report (EPAR) on the European Medicines Agency (EMA) website.</p><p>When used with other antiretroviral medicinal products in cell culture, the combination of maraviroc was not antagonistic with a range of NRTIs ,NNRTIs, PIs or the HIV fusion inhibitor enfuvirtide.</p><p><u>Virologic Escape</u></p><p>Virologic escape from maraviroc&nbsp;can occur via 2 routes: the emergence of pre-existing virus which can use CXCR4 as its entry co-receptor (CXCR4-using virus) or the selection of virus that continues to use exclusively drug-bound CCR5 (CCR5-tropic virus).&nbsp;</p><p><em><u>In vitro: </u></em></p><p>HIV-1 variants with reduced susceptibility to maraviroc have been selected <em>in vitro</em>, following serial passage of two CCR5-tropic viruses (0 laboratory strains, 2 clinical isolates).&nbsp;The maraviroc-resistant viruses remained CCR5-tropic and there was no conversion from a CCR5-tropic virus to a CXCR4-using virus.</p><p><em>Phenotypic resistance:</em></p><p>Concentration response curves for the maraviroc-resistant viruses were characterized phenotypically&nbsp;by curves that did not reach 100% inhibition in assays using serial dilutions of maraviroc (&lt;100% maximal percentage inhibition (MPI)). Traditional IC<sub>50</sub>/IC<sub>90</sub> fold-change was not a useful parameter to measure phenotypic resistance, as those values were sometimes unchanged despite significantly reduced sensitivity.</p><p><em>Genotypic resistance:</em></p><p>Mutations were found to accumulate in the gp120&nbsp;envelope glycoprotein&nbsp; (the&nbsp;viral&nbsp;protein that binds to the&nbsp;CCR5 co-receptor). The position of these mutations was not consistent between different isolates. Hence, the relevance of these mutations to maraviroc susceptibility in other viruses is not known.</p><p><em>Cross-resistance in vitro:&nbsp; </em></p><p>HIV-1 clinical isolates resistant to NRTIs, NNRTIs, PIs and enfuvirtide were all susceptible to maraviroc in cell culture. Maraviroc-resistant viruses that emerged <em>in vitro</em> remained sensitive to the fusion inhibitor enfuvirtide and the PI, saquinavir.</p><p><em><u>In vivo:</u></em></p><p><em>Treatment Experienced Adult Patients</em></p><p>In the pivotal studies (MOTIVATE 1 and MOTIVATE 2), 7.6% of patients had a change in tropism result from CCR5-tropic to CXCR4-tropic or dual/mixed-tropic between screening and baseline (a period of 4-6 weeks).&nbsp;&nbsp;</p><p><u>Failure with CXCR4-using virus:</u></p><p>CXCR4-using virus&nbsp;was detected at failure in approximately 60% of&nbsp;subjects who failed treatment on maraviroc, as compared to 6% of&nbsp;subjects who experienced treatment failure in the placebo + OBT &nbsp;arm. To investigate the likely origin of the on-treatment CXCR4-using virus, a detailed clonal analysis was conducted on virus from 20 representative subjects (16 subjects from the maraviroc arms and 4 subjects from the placebo + OBT &nbsp;arm) in whom CXCR4-using virus was detected at treatment failure. This analysis indicated that CXCR4-using virus emerged from a pre-existing CXCR4-using reservoir not detected at baseline, rather than from mutation of CCR5-tropic virus present at baseline.&nbsp; An analysis of tropism following failure of maraviroc therapy with CXCR4&nbsp;-using&nbsp;virus in patients with CCR5 virus at baseline, demonstrated that the virus population reverted back to CCR5 tropism in 33 of 36 patients with more than 35 days of follow up.&nbsp;</p><p>At the time of failure with&nbsp;CXCR4-using&nbsp;virus, the resistance pattern to other antiretrovirals appears similar to that of the CCR5-tropic population at baseline, based on available data. Hence, in the selection of a treatment regimen, it should be assumed that viruses&nbsp;forming part of the previously&nbsp;undetected&nbsp;CXCR4&nbsp;-using&nbsp;population (i.e. minor viral population) harbours the same resistance pattern as the CCR5-tropic&nbsp;population.</p><p><u>Failure with CCR5-tropic virus:</u></p><p><em>Phenotypic resistance </em></p><p>In patients with CCR5-tropic virus at time of treatment failure with maraviroc, 22 out of 58 patients&nbsp;had&nbsp;virus with reduced sensitivity to maraviroc.&nbsp;In the remaining 36 patients,&nbsp;there was no evidence of virus with reduced sensitivity as identified&nbsp;by exploratory virology analyses on a representative group. The latter group had markers correlating to low compliance (low and variable drug levels and often a calculated high residual sensitivity score of the OBT). In patients failing therapy with CCCR5-tropic virus only, maraviroc might be considered still active if the MPI value is &ge;95% (PhenoSense Entry assay). Residual activity in vivo for viruses with MPI-values &lt;95% has not been determined.</p><p><em>Genotypic resistance </em></p><p>A relatively small number of individuals receiving maraviroc-containing therapy have failed with phenotypic resistance (i.e. the ability to use drug-bound CCR5 with MPI &lt;95%).&nbsp;&nbsp; To date, no signature mutation(s) have been identified.&nbsp; The gp120 amino acid substitutions identified so far are context dependent and inherently unpredictable with regards to maraviroc susceptibility.</p><p><em>Treatment-Experienced Paediatric Patients</em></p><p>In the Week 48 analysis (N=103), non-CCR5 tropic-virus was detected in 5/23 (22%) subjects at virologic failure. One additional subject had CCR5 tropic-virus with reduced susceptibility to maraviroc at virologic failure, although this was not retained at the end of treatment.&nbsp; Subjects with virologic failure generally appeared to have low compliance to both maraviroc and the background antiretroviral elements of their regimens. Overall, the mechanisms of resistance to maraviroc observed in this treatment-experienced paediatric population were similar to those observed in adult populations.</p><p><u>Clinical results</u></p><p><em><u>Studies in Treatment-Experienced Adult Patients Infected with CCR5-tropic Virus:</u></em></p><p>The clinical efficacy of maraviroc (in combination with other antiretroviral medicinal products) on plasma HIV RNA levels and CD4+ cell counts&nbsp; have been investigated in two pivotal, randomized, double blind, multicentre studies (MOTIVATE 1 and MOTIVATE 2, n=1076 ) in patients infected with CCR5 tropic HIV-1 as determined by the Monogram Trofile Assay.</p><p>Patients who were eligible for these studies had prior exposure to at least 3 antiretroviral medicinal product classes [&ge;1 NRTIs, &ge;1 NNRTIs, &ge;2 PIs, and/or enfurvirtide] or documented resistance to at least one member of each class. Patients were randomised in a 2:2:1 ratio to maraviroc 300&nbsp;mg (dose equivalence) once daily, twice daily or placebo in combination with an optimized background consisting of 3 to 6 antiretroviral medicinal products (excluding low-dose ritonavir). The OBT was selected on the basis of the subject&rsquo;s prior treatment history and baseline genotypic and phenotypic viral resistance measurements.</p><p>&nbsp;</p><p><strong>Table </strong><strong>5:&nbsp; Demographic and baseline characteristics of patients </strong><strong>&nbsp;(pooled studies MOTIVATE 1 and MOTIVATE 2</strong><strong>)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:674px"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Demographic and Baseline Characteristics</strong></p></td><td style="vertical-align:top"><p><strong>Maraviroc 300&nbsp;mg twice daily</strong></p><p><strong>+ OBT</strong></p><p><strong>&nbsp;</strong></p><p><strong>N = 426</strong></p></td><td style="vertical-align:top"><p><strong>Placebo + OBT </strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>N = 209</strong></p></td></tr><tr><td style="vertical-align:top"><p>Age (years)</p><p>(Range, years)</p></td><td style="vertical-align:top"><p>46.3</p><p>21-73</p></td><td style="vertical-align:top"><p>45.7</p><p>29-72</p></td></tr><tr><td style="vertical-align:top"><p>Male Sex</p></td><td style="vertical-align:top"><p>89.7%</p></td><td style="vertical-align:top"><p>88.5%</p></td></tr><tr><td style="vertical-align:top"><p>Race (White/Black/Other)</p></td><td style="vertical-align:top"><p>85.2% / 12% / 2.8%</p></td><td style="vertical-align:top"><p>85.2% / 12.4% / 2.4%</p></td></tr><tr><td style="vertical-align:top"><p>Mean Baseline HIV-1 RNA (log<sub>10</sub> copies/mL)</p></td><td style="vertical-align:top"><p>4.85</p></td><td style="vertical-align:top"><p>4.86</p></td></tr><tr><td style="vertical-align:top"><p>Median Baseline CD4+ Cell Count (cells/mm<sup>3</sup>)</p><p>(range, cells/mm<sup>3</sup>)</p></td><td style="vertical-align:top"><p>166.8</p><p>(2.0-820.0)</p></td><td style="vertical-align:top"><p>171.3</p><p>(1.0-675.0)</p></td></tr><tr><td style="vertical-align:top"><p>Screening Viral Load <u>&gt;</u>100,000 copies/mL</p></td><td style="vertical-align:top"><p>179 (42.0%)</p></td><td style="vertical-align:top"><p>84 (40.2%)</p></td></tr><tr><td style="vertical-align:top"><p>Baseline CD4+ Cell Count&nbsp; &le;200 cells/mm<sup>3</sup></p></td><td style="vertical-align:top"><p>250 (58.7%)</p></td><td style="vertical-align:top"><p>118 (56.5%)</p></td></tr><tr><td style="vertical-align:top"><p>Number (Percentage) of patients with GSS score<sup>1</sup>:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;3</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>102 (23.9%)</p><p>138 (32.4%)</p><p>80 (18.8%)</p><p>104 (24.4%)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>51 (24.4%)</p><p>53 (25.4%)</p><p>41 (19.6%)</p><p>59 (28.2%)</p></td></tr></tbody></table><p><sup>1</sup>Based on GeneSeq<strong><em> </em></strong>resistance assay<strong><em> </em></strong></p><p><strong><em>&nbsp;</em></strong></p><p>Limited numbers of patients from ethnicities other than Caucasian were included in the pivotal clinical studies, therefore very limited data are available in these patient populations.</p><p>The mean increase in CD4+ cell count from baseline in patients who failed with a change in tropism result to dual/mixed tropic or CXCR4, in the maraviroc 300&nbsp;mg twice daily + OBT (+56&nbsp;cells/mm<sup>3</sup>) group was greater than that seen in patients failing placebo + OBT &nbsp;(+13.8&nbsp;cells/mm<sup>3</sup>) regardless of tropism.</p><p><strong>Table </strong><strong>6.</strong><strong> Efficacy Outcomes at week 48 (pooled studies MOTIVATE 1 and MOTIVATE 2)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:607px"><tbody><tr><td style="vertical-align:top"><p><strong>Outcomes</strong></p></td><td style="vertical-align:top"><p><strong>Maraviroc</strong><strong> 300&nbsp;mg</strong></p><p><strong>twice daily</strong></p><p><strong>+ OBT<br />&nbsp;&nbsp;&nbsp;&nbsp; N=426</strong></p></td><td style="vertical-align:top"><p><strong>Placebo + OBT </strong></p><p><br />&nbsp;</p><p><strong>N=209</strong></p></td><td style="vertical-align:top"><p><strong>Difference<sup>1</sup></strong></p><p><strong>&nbsp;(Confidence Interval<sup>2</sup>)</strong></p></td></tr><tr><td style="vertical-align:top"><p>HIV-1 RNA</p><p>Mean change from baseline</p><p>(log copies/mL)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-1.837</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-0.785</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>-1.055</p><p>(-1.327, -0.783)</p></td></tr><tr><td style="vertical-align:top"><p>Percentage of patients with HIV-1 RNA &lt;400 copies/mL</p></td><td style="vertical-align:top"><p>56.1%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>22.5%</p></td><td style="vertical-align:top"><p>Odds ratio: 4.76</p><p>(3.24, 7.00)</p></td></tr><tr><td style="vertical-align:top"><p>Percentage of patients with HIV-1 RNA &lt;50 copies/mL</p></td><td style="vertical-align:top"><p>45.5%</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>16.7%</p></td><td style="vertical-align:top"><p>Odds ratio: 4.49</p><p>(2.96, 6.83)</p></td></tr><tr><td style="vertical-align:top"><p>CD4+ cell count</p><p>Mean change from baseline (cells/&micro;L)</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>122.78</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>59.17</p><p>&nbsp;</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>63.13</p><p>(44.28, 81.99)</p></td></tr></tbody></table><p><sup>1</sup><sup> </sup>p-values &lt; 0.0001</p><p><sup>2</sup> For all efficacy endpoints the confidence intervals were 95%, except for HIV-1 RNA Change from baseline which was 97.5%</p><p>&nbsp;</p><p>In a retrospective analysis of the MOTIVATE studies with a more sensitive assay for screening of tropism (Trofile ES), the response rates (&lt;50 copies/mL at week 48) in patients with only CCR5-tropic virus detected at baseline was 48.2% in those treated with maraviroc + OBT (n=328), and 16.3% in those treated with placebo + OBT (n=178).</p><p>Maraviroc 300&nbsp;mg twice daily + OBT was superior to placebo + OBT across all subgroups of patients analysed (see Table 7).<strong> </strong>Patients with very low CD4+ count at baseline (i.e. &lt;50 cells/ &micro;L) had a less favourable outcome. This subgroup had a high degree of bad prognostic markers, i.e. extensive resistance and high baseline viral loads. However, a significant treatment benefit for maraviroc compared to placebo + OBT was still demonstrated (see Table 7).</p><p>&nbsp;</p><p><strong>Table </strong><strong>7: Proportion of patients achieving &lt;50&nbsp;copies/mL at Week 48 by subgroup (pooled Studies MOTIVATE 1 and MOTIVATE 2)</strong></p><table border="1" cellspacing="0" cellpadding="0" style="width:595px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Subgroups</strong></p></td><td colspan="2" style="vertical-align:top"><p><strong>HIV-1 RNA &lt;50&nbsp;copies/mL</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Maraviroc</strong><strong> 300&nbsp;mg</strong></p><p><strong>twice daily</strong></p><p><strong>+ OBT<br />N=426</strong></p></td><td style="vertical-align:top"><p><strong>Placebo + OBT </strong></p><p><strong>&nbsp;</strong></p><p><strong>N=209</strong></p></td></tr><tr><td style="vertical-align:top"><p>Screening HIV-1 RNA (copies /mL):</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;100,000</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;100,000</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>58.4%</p><p>&nbsp;34.7%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>&nbsp;26.0%</p><p>9.5%</p></td></tr><tr><td style="vertical-align:top"><p>Baseline CD4+ (cells/ &micro;L):&nbsp;&nbsp;</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &lt;50</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 50-100</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 101-200</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 201-350</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge; 350</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>16.5%</p><p>36.4%</p><p>56.7%</p><p>57.8%</p><p>72.9%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2.6%</p><p>12.0%</p><p>21.8%</p><p>21.0%</p><p>38.5%</p></td></tr><tr><td style="vertical-align:top"><p>Number of active ARVs in OBT<sup>1<s>,2</s></sup>:</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 0</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 1</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 2</p><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &ge;3</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>32.7%</p><p>&nbsp;44.5%</p><p>&nbsp;58.2%</p><p>&nbsp;62%</p></td><td style="vertical-align:top"><p>&nbsp;</p><p>2.0%</p><p>&nbsp;7.4%</p><p>&nbsp;31.7%</p><p>&nbsp;38.6%</p></td></tr></tbody></table><p><sup>1</sup>Based on GSS.</p><p>&nbsp;</p><p><em><u>Studies in Treatment-Experienced Adult Patients Infected with Non-CCR5-tropic Virus</u></em></p><p>Study A4001029 was an exploratory study in patients infected with dual/mixed or CXCR4 tropic&nbsp; HIV-1 with a similar design as the studies MOTIVATE 1 and MOTIVATE 2. Use of maraviroc was not associated with a significant decrease in HIV 1 RNA compared with placebo in these subjects and no adverse effect on CD4+ cell count was noted.</p><p><em><u>Studies in Treatment‑Na&iuml;ve Adult Patients Infected with CCR5-tropic Virus</u></em></p><p>A randomised, double-blinded study (MERIT) explored maraviroc versus efavirenz, both in combination with zidovudine/lamivudine (n=721, 1:1). After 48 weeks of treatment, maraviroc did not reach non-inferiority to efavirenz for the endpoint of HIV-1 RNA &lt; 50 copies/mL (65.3 vs. 69.3 % respectively, lower confidence bound -11.9%). More patients treated with maraviroc discontinued due to lack of efficacy (43 vs.15) and among patients with lack of efficacy, the proportion acquiring NRTI resistance (mainly lamivudine) was higher in the maraviroc arm. Fewer patients discontinued maraviroc due to adverse events (15 vs. 49).</p><p><em><u>Studies in Adult Patients Co-infected with Hepatitis B and/or Hepatitis C virus</u></em><!--[if supportFields]><i><u><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_b9670158-e17c-49a0-9392-0ee037a884f2 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u></i><![endif]--><em><u>&nbsp;</u></em><!--[if supportFields]><i><u><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span></u></i><![endif]--></p><p>The hepatic safety of maraviroc in combination with other antiretroviral agents in CCR5-tropic HIV-1-infected subjects with HIV RNA &lt;50 copies/mL, co-infected with Hepatitis C and/or Hepatitis B Virus was evaluated in a multicentre, randomized, double blinded, placebo-controlled&nbsp; study. 70 subjects (Child-Pugh Class A, n=64; Child-Pugh Class B, n=6) were randomized to the maraviroc group and 67 subjects (Child-Pugh Class A, n=59; Child-Pugh Class B, n=8) were randomized to the placebo group.</p><p>The primary objective assessed the incidence of Grade 3 and 4 ALT abnormalities (&gt;5x upper limit of normal (ULN) if baseline ALT &le; ULN; or &gt;3.5x baseline if baseline ALT &gt; ULN) at Week 48. One subject in each treatment arm met the primary endpoint by Week 48 (at Week 8 for placebo and Week 36 for the maraviroc arm).&nbsp;</p><p><em><u>Studies in Treatment‑Experienced Paediatric Patients Infected with CCR5-tropic Virus</u></em><!--[if supportFields]><i><u><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_2e924336-f9a8-4241-84d8-0b234dfdd9e3 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span></u></i><![endif]--><em><u>&nbsp;</u></em><!--[if supportFields]><i><u><span
style='mso-bidi-font-size:11.0pt'><span style='mso-element:field-end'></span></span></u></i><![endif]--></p><p>Study A4001031 is an open-label, multicenter trial in paediatric patients (aged 2&nbsp;years to less than 18 years) infected with CCR5‑tropic HIV‑1, determined by the enhanced-sensitivity Trofile assay.</p><p>Subjects were required to have HIV‑1 RNA greater than 1,000&nbsp;copies per mL at Screening.</p><p>All subjects (n&nbsp;=&nbsp;103) received maraviroc twice daily and OBT.&nbsp; Maraviroc dosing was based on body surface area and doses were adjusted based on whether the subject was receiving potent CYP3A inhibitors and/or inducers.</p><p>In paediatric patients with a successful tropism test, dual mixed/CXCR4-tropic virus was detected in around 40% of screening samples (8/27, 30% in 2-6 year-olds, 31/81, 38% in 6-12 year-olds and 41/90, 46% in 12-18 year-olds), underscoring the importance of tropism testing also in the paediatric population.</p><p>The population was 52% female and 69% black, with mean age of 10&nbsp;years (range: 2&nbsp;years to 17&nbsp;years). At baseline, mean plasma HIV-1 RNA was 4.3&nbsp;log<sub>10</sub>&nbsp;copies/mL (range 2.4 to 6.2 log<sub>10</sub> copies per mL), mean CD4+ cell count was 551&nbsp;cells/mm<sup>3</sup> (range 1 to 1654&nbsp;cells/mm<sup>3</sup>) and mean CD4+ % was 21% (range 0% to 42%).</p><p>At 48&nbsp;weeks, using a missing, switch or discontinuation equals failure analysis, 48% of subjects treated with maraviroc and OBT achieved plasma HIV-1 RNA less than 48&nbsp;copies/mL and 65% of subjects achieved plasma HIV-1 RNA less than 400 copies per mL. The mean CD4+ cell count (percent) increase from baseline to Week&nbsp;48 was 247&nbsp;cells/mm<sup>3</sup> (5%).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption: </u></p><p>The absorption of maraviroc is variable with multiple peaks. Median peak maraviroc plasma concentrations are attained at 2 hours (range 0.5-4&nbsp;hours) following single oral doses of 300&nbsp;mg commercial tablet administered to healthy volunteers. The pharmacokinetics of oral maraviroc are not dose proportional over the dose range. The absolute bioavailability of a 100&nbsp;mg dose is 23% and is predicted to be 33% at 300&nbsp;mg. Maraviroc is a substrate for the efflux transporter P-glycoprotein.</p><p>Co-administration of a 300&nbsp;mg tablet with a high fat breakfast reduced maraviroc C<sub>max</sub> and AUC by 33% and co-administration of 75 mg of oral solution with a high fat breakfast reduced maraviroc AUC by 73% in adult healthy volunteers. Studies with the tablets demonstrated a reduced food-effect at higher doses.</p><p>There were no food restrictions in the adult studies (using tablet formulations) or in the paediatric study (using both tablet and oral solution formulations). &nbsp;The results did not indicate any relevant efficacy or safety concern related to either fed or fasted dosing conditions. Therefore, maraviroc tablets and oral solution can be taken with or without food at the recommended doses in adults (see section 4.2).</p><p><u>Distribution</u></p><p>Maraviroc is bound (approximately 76%) to human plasma proteins, and shows moderate affinity for albumin and alpha-1 acid glycoprotein. The volume of distribution of maraviroc is approximately 194&nbsp;L.</p><p><u>Biotransformation </u></p><p>Studies in humans and <em>in vitro</em> studies using human liver microsomes and expressed enzymes have demonstrated that maraviroc is principally metabolized by the cytochrome P450 system to metabolites that are essentially inactive against HIV-1. <em>In vitro</em> studies indicate that CYP3A4 is the major enzyme responsible for maraviroc metabolism. <em>In vitro</em> studies also indicate that polymorphic enzymes CYP2C9, CYP2D6 and CYP2C19 do not contribute significantly to the metabolism of maraviroc.<strong><em> </em></strong></p><p>Maraviroc is the major circulating component (approximately 42% radioactivity) following a single oral dose of 300&nbsp;mg. The most significant circulating metabolite in humans is a secondary amine (approximately 22% radioactivity) formed by N-dealkylation. This polar metabolite has no significant pharmacological activity. Other metabolites are products of mono-oxidation and are only minor components of plasma radioactivity.</p><p><u>Elimination </u></p><p>A mass balance/excretion study was conducted using a single 300&nbsp;mg dose of <sup>14</sup>C-labeled maraviroc. Approximately 20% of the radiolabel was recovered in the urine and 76% was recovered in the faeces over 168&nbsp;hours. Maraviroc was the major component present in urine (mean of 8% dose) and faeces (mean of 25% dose). The remainder was excreted as metabolites. After intravenous administration (30&nbsp;mg), the half-life of maraviroc was 13.2 h, 22% of the dose was excreted unchanged in the urine and the values of total clearance and renal clearance were 44.0 L/h and 10.17 L/h respectively.</p><p><u>Special patient populations:</u></p><p><em>Elderly</em></p><p>Population analysis of the Phase 1/2a and Phase 3 studies (16-65 years of age) has been conducted and no effect of age have been observed (see section 4.2).</p><p><em>Renal impairment: </em></p><p>A study compared the pharmacokinetics of a single 300 mg dose of maraviroc in</p><p>subjects with severe renal impairment (CLcr &lt; 30 mL/min, n=6) and end stage renal disease (ESRD) to healthy volunteers (n=6). The geometric mean AUCinf (CV%) for maraviroc was as follows: healthy volunteers (normal renal function) 1348.4 ng&middot;h/mL (61%); severe renal impairment 4367.7 ng&middot;h/mL (52%); ESRD (dosing after dialysis) 2677.4 ng&middot;h/mL (40%); and ESRD (dosing before dialysis) 2805.5 ng&middot;h/mL (45%). The C max (CV%) was 335.6 ng/mL (87%) in healthy volunteers (normal renal function); 801.2 ng/mL (56%) in severe renal impairment ; 576.7 ng/mL (51%) in ESRD (dosing after dialysis) and 478.5 ng/mL (38%) in ESRD (dosing before dialysis). Dialysis had a minimal effect on exposure in subjects with ESRD. Exposures observed in subjects with severe renal impairment and ESRD were within the range observed in single maraviroc 300 mg dose studies in healthy volunteers with normal renal function. Therefore, no dose adjustment is necessary in patients with renal impairment receiving maraviroc without a potent CYP3A4 inhibitor (see sections 4.2, 4.4 and 4.5).</p><p>In addition, the study compared the pharmacokinetics of multiple dose maraviroc in combination with saquinavir/ritonavir 1000/100 mg BID (a potent CYP3A4 inhibitor) for 7 days in subjects with mild renal impairment (CLcr &gt;50 and &pound;80 mL/min, n=6) and moderate renal impairment (CLcr &sup3;30 and &pound;50 mL/min, n=6) to healthy volunteers (n=6). Subjects received 150 mg of maraviroc at different dose frequencies (healthy volunteers &ndash; every 12 hours; mild renal impairment &ndash; every 24 hours; moderate renal impairment &ndash; every 48 hours). The average concentration (Cavg) of</p><p>maraviroc over 24 hours was 445.1 ng/mL, 338.3 ng/mL, and 223.7 ng/mL for subjects with normal renal function, mild renal impairment, and moderate renal impairment, respectively. The Cavg of maraviroc from 24-48 hours for subjects with moderate renal impairment was low (Cavg: 32.8 ng/mL). Therefore, dosing frequencies of longer than 24 hours in subjects with renal impairment may result in inadequate exposures between 24-48 hours. Dose adjustment is necessary in patients with renal impairment receiving maraviroc with potent CYP3A4 inhibitors (see sections 4.2 and 4.4 and 4.5).</p><p><em>Hepatic impairment</em></p><p>Maraviroc is primarily metabolized and eliminated by the liver.&nbsp;A study compared the pharmacokinetics of a single 300&nbsp;mg dose of maraviroc &nbsp;in patients with mild (Child-Pugh Class A, n=8), and moderate (Child-Pugh Class B, n=8) hepatic impairment compared to healthy subjects (n=8). Geometric mean ratios for Cmax and AUC<sub>last</sub> were 11% and 25% higher respectively for subjects with mild hepatic impairment, and 32% and 46% higher respectively for subjects with moderate hepatic impairment compared to subjects with normal hepatic function.&nbsp;The effects of moderate hepatic impairment may be underestimated due to limited data in patients with decreased metabolic capacity and higher renal clearance in these subjects. The results should therefore be interpreted with caution. The pharmacokinetics of maraviroc has not been studied in subjects with severe hepatic impairment (see sections 4.2 and 4.4).</p><p><u>Race </u></p><p>No relevant difference between Caucasian, Asian and Black subjects has been observed.&nbsp; The pharmacokinetics in other races has not been evaluated.</p><p><u>Gender </u></p><p>No relevant differences in pharmacokinetics have been observed.</p><p><u>Pharmacogenomics</u></p><p>The pharmacokinetics of maraviroc is dependent on CYP3A5 activity and expression level, which can be modulated by genetic variation. Subjects with a functional CYP3A5 (CYP3A5*1 allele) have been shown to have a reduced exposure to maraviroc compared to subjects with defect CYP3A5 activity (e.g., CYP3A5*3, CYP3A5*6, and CYP3A5*7). The <em>CYP3A5</em> allelic frequency depends on ethnicity: the majority of Caucasians (~90%) are poor metabolisers of CYP3A5 substrates (i.e., subjects with no copy of functional <em>CYP3A5</em> alleles) while approximately 40% of African-Americans and 70% of Sub-Saharan Africans are extensive metabolisers (i.e., subjects with two copies of functional <em>CYP3A5</em> alleles).</p><p>In a Phase 1 study conducted in healthy subjects, Blacks with a CYP3A5 genotype conferring extensive maraviroc metabolism (2 CYP3A5*1 alleles; n=12) had a 37% and 26% lower AUC when dosed with maraviroc 300 mg twice daily compared with Black (n=11) and Caucasian (n=12) subjects with CYP3A5 genotype conferring poor maraviroc metabolism (no CYP3A5*1 allele), respectively. The difference in maraviroc exposure between CYP3A5 extensive and poor metabolisers was reduced when maraviroc was administered together with a strong CYP3A inhibitor: extensive CYP3A5 metabolisers (n=12) had a 17% lower maraviroc AUC compared with poor CYP3A5 metabolisers (n=11) when dosed with maraviroc 150 mg once daily in the presence of darunavir/cobicistat (800/150 mg).</p><p>All subjects in the Phase 1 study achieved the Cavg concentrations that have been shown to be associated with near maximal virologic efficacy with maraviroc (75 ng/mL) in the Phase 3 study in treatment‑na&iuml;ve adult patients (MERIT).&nbsp; Therefore, despite differences in CYP3A5 genotype prevalence by race, the effect of CYP3A5 genotype on maraviroc exposure is not considered clinically significant and no maraviroc dose adjustment according to CYP3A5 genotype, race or ethnicity is needed.<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ansi-language:EN-GB;font-weight:
normal'><span style='mso-element:field-begin'></span> DOCVARIABLE
vault_nd_2ba7e84c-ab9c-47de-9dfc-731d6e0919ef \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='font-family:"Times New Roman",serif;mso-ansi-language:EN-GB;font-weight:
normal'><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Primary pharmacological activity (CCR5 receptor affinity) was present in the monkey (100% receptor occupancy) and limited in the mouse, rat, rabbit and dog. In mice and human beings that lack CCR5 receptors through genetic deletion, no significant adverse consequences have been reported.</p><p>&nbsp;</p><p><em>In vitro</em> and <em>in vivo</em> studies showed that maraviroc has a potential to increase QTc interval at supratherapeutic doses with no evidence of arrhythmia.</p><p>&nbsp;</p><p>Repeated dose toxicity studies in rats identified the liver as the primary target organ for toxicity (increases in transaminases, bile duct hyperplasia, and necrosis).</p><p>&nbsp;</p><p>Maraviroc was evaluated for carcinogenic potential by a 6 month transgenic mouse study and a 24 month study in rats. In mice, no statistically significant increase in the incidence of tumours was reported at systemic exposures from 7 to 39-times the human exposure (unbound AUC 0-24h measurement) at a dose of 300&nbsp;mg twice daily. In rats, administration of maraviroc at a systemic exposure 21-times the expected human exposure produced thyroid adenomas associated with adaptive liver changes. These findings are considered of low human relevance. In addition, cholangiocarcinomas (2/60 males at 900 mg/kg) and cholangioma (1/60 females at 500 mg/kg) were reported in the rat study at a systemic exposure at least 15-times the expected free human exposure.</p><p>&nbsp;</p><p>Maraviroc was not mutagenic or genotoxic in a battery of in vitro and in vivo assays including bacterial reverse mutation, chromosome aberrations in human lymphocytes and mouse bone marrow micronucleus.</p><p>&nbsp;</p><p>Maraviroc did not impair mating or fertility of male or female rats, and did not affect sperm of treated male rats up to 1000&nbsp;mg/kg. The exposure at this dose level corresponded to 39-fold the estimated free clinical AUC for a 300&nbsp;mg twice daily dose.</p><p>&nbsp;</p><p>Embryofoetal development studies were conducted in rats and rabbits at doses up to 39- and 34-fold the estimated free clinical AUC for a 300&nbsp;mg twice daily dose. In rabbit, ,7 foetuses had external anomalies at maternally toxic doses and 1 foetus at the mid dose of 75 mg/kg.</p><p>&nbsp;</p><p>Pre- and post-natal developmental studies were performed in rats at doses up to 27-fold the estimated free clinical AUC for a 300&nbsp;mg twice daily dose. A slight increase in motor activity in high-dose male rats at both weaning and as adults was noted, while no effects were seen in females. Other developmental parameters of these offspring, including fertility and reproductive performance, were not affected by the maternal administration of maraviroc.<!--[if supportFields]><span
style='mso-bidi-font-weight:bold'><span style='mso-element:field-begin'></span>
DOCVARIABLE vault_nd_06d51fa4-bd48-440c-829a-5c17e7bafeb7 \* MERGEFORMAT <span
style='mso-element:field-separator'></span></span><![endif]-->&nbsp;<!--[if supportFields]><span
style='mso-bidi-font-weight:bold'><span style='mso-element:field-end'></span></span><![endif]--></p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Tablet core:</u></p><p>Cellulose, microcrystalline</p><p>Calcium hydrogen phosphate, anhydrous</p><p>Sodium starch glycolate</p><p>Magnesium stearate</p><p>&nbsp;</p><p><u>Film-coat:</u>&nbsp;</p><p>Poly (vinyl alcohol)</p><p>Titanium dioxide</p><p>Macrogol 3350</p><p>Talc</p><p>Soya lecithin</p><p>Indigo carmine aluminium lake (E132)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The expiry date is indicated on the outer package.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Do not store above 30&deg;C</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>High density polyethylene bottles (HDPE) with polypropylene child resistant (CR) closures and an aluminium foil/polyethylene heat induction seal containing 180 film-coated tablets.</p><p>&nbsp;</p><p>Polyvinyl chloride (PVC) blisters with child-resistant (CR) aluminium/polyethylene terephthalate (PET) lidding foil in a carton containing 30, 60, 90 film-coated tablets and multipacks containing 180 (2 packs of 90) film-coated tablets.</p><p>&nbsp;</p><p>Not all pack sizes may be marketed.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p><p>&nbsp;</p><p><strong>Celsentri</strong> is a trademark owned by or licenced to ViiV Healthcare group of companies.</p><p>&copy; 2024 ViiV Healthcare group of companies. All rights reserved.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Manufacturing: 
Pfizer Manufacturing Deutschland GmbH Betriebsstatte Freiburg, Mooswaldallee 1,79090 Freiburg, Germany

Marketing Authorisation Holder:
Glaxo Saudi Arabia Ltd.*, Jeddah, Kingdom of Saudi Arabia
*member of GSK group of companies

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Version Number: EMAv13
Date of Revision of the Text: 19 August 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>